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RNA ribonucleic acid 
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2. Introduction 
Structure and function of the zona pellucida 
The zona pellucida (ZP) is acellular glycoproteinmatrix, which surrounds the oocytes of all 
mammals (Chiu et al. 2014). Depending on the mammalian species (Table 1), the ZP is 
7 - 20 µm thick and composed of 3-4 glycopro-teins which is designated as ZP 
glycoprotein-1 (ZP1), ZP2, ZP3 and ZP4 (Gupta et al. 2012). ZP is responsible for sperm-
egg contact and thereby for fertilization. ZP1 and ZP4 are paralogous genes and share a 
common ancestor  whereas ZP2 and ZP3 are relevant for ZP development and gamete 
recognition (Conner and Hughes 2003; Spargo 2002). Mice don’t have a ZP4 in their egg 
coat, but they carry the gene (Goudet et al. 2008). The same accounts for bovine and 
canine ZP, but here it is ZP1, which is not integrated. The basic structure of the egg surface 
has been conserved over millions of years (Monné et al. 2006) and homologous genes to 
ZP1-4 building up the vitelline envelope of non-mammalian vertebrates and marine 
invertebrates, like mollusks and ascidians (Monné and Jovine 2011). For instance, humane 
ZP2 has an amino acid similarity of 57, 64, 94 % to murine, porcine and bonnet monkey 
ZP2, but humane ZP3 has 67, 74, 94 % similarity to murine, porcine and bonnet monkey 
ZP3, respectively (Chiu et al. 2014). Binding between sperm’s ZP receptors at the 
acrosome membrane and ZP’s sperm receptors initiate acrosome reaction and due to 
structural ZP changes, referred to as zona hardening, block polyspermy (Nixon et al. 2007). 
Despite of decades of research, the exact mechanism of fertilization is not totally revealed 
(Monné and Jovine 2011; Wassarman et al. 2001). 
Table 1: Overview of ZP composition in different mammals (Goudet et al. 2008). Points (●) in 
brackets indicate pseudogene, which are not translated. ZP1 and ZP4 are 
paralogous. 
Species ZP1 ZP2 ZP3 ZP4 
Pig  ● ● ● 
Dog (●) ● ● ● 
Cow (●) ● ● ● 
Cat  ● ● ● 
Rabbit  ● ● ● 
Human ● ● ● ● 
Mouse ● ● ● (●) 
Rat ● ● ● ● 
Hamster ● ● ● ● 
Bonnet monkey ● ● ● ● 
 
It is reported (Wassarman 1999; Greve and Wassarman 1985) that ZP1 acts as 
interconnection between ZP2/ZP3 heterocomplexes and builds up a filamentous structure 
(Figure 1A). Sperm binds to ZP, although ZP1 is lacking after mutation (Rankin et al. 1999). 
ZP2 and ZP3 are critical for the ZP structure. This was shown with ZP2 and ZP3 null mice, 
which produced no ZP and were infertile (Rankin et al. 2001; Rankin et al. 1998).  
The sperm binds to ZP2 or ZP3 and penetrates the ZP by kinetic force of the flagellum 
or/and enzymatic reaction (Saldívar-Hernández et al. 2015) (Figure 1C). After reaching the 
perivitelline space (PVS) gametes membranes fuse and enzymes from exocytosed 
granules block the binding of a second sperm. 
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Due to the blocking of the contact between sperm and egg by mutating ZP2 (Sun 1999; 
Hasegawa et al. 1988; East et al. 1984) or ZP3 (Litscher et al. 2009; Kinloch et al. 1995; 
Millar et al. 1989), it still remains controversial that, which of the both ZP proteins is the 
actual receptor recognizing sperm contact (Dean 2004) (Figure 1B). It seems important in 
term of the taxon-specific fertilization. The swapping and site-directed mutagenesis in the 
murine mZP3 exon-7 (Kinloch et al. 1995) governing the species-specificity in sperm-egg 
interaction (Swanson et al. 2001). Avella et al. 2014 supported the ZP2 model. Here, 
human sperm binds only to murine ZP, when a human ZP2 epitope (amino acid 55 - 88) 
was integrate into murine ZP2 by genetic modifications. Although it could be assumed, 
that a total distinction of species specific fertilization is not based on the molecular 
mechanism at all which is supported by the literature (Sinowatz et al. 2001). In some 
cases, sperm is able to bind different species (Lanzendorf et al. 1992; Yoshimatsu et al. 
1988; Swenson and Dunbar 1982; Bedford 1977). The morphology of the sexual organs 
and times of fecundity or mating rituals are only some factors defining the reproduction 
of the species. When these barriers are artificially broken down, then it could be possible 
to create a new living creature, like the hinny or liger (Rong et al. 1988). 
 
Figure 1: (A) Postulated ZP filament structure from chicken (adopted from Han et al. 2010).  This 
imagination of ZP structure is similar to that of mice ZP. (B) Models of gamete 
recognition (Avella et al. 2013). When ZP3 is assumed as primary sperm receptor 
(left side), gamete binding is mediated by O-glycosylation at the C-terminus. 
Polyspermy is blocked by enzymatic digestion of the O-glycans. ZP2 as primary 
sperm binding site at the N-terminus (right side) (adopted from Avella et al. 2014). 
Enzymatic restriction destroys sperm binding site and disable second sperm 
binding. (C) Model of gamete recognition (adopted from Avella et al. 2014). Sperm 
bind to ZP2 at the surface of ZP (aquamarine). After reaching the perivitelline space 
(PVS) gametes membrane get fussed and polyspermy is blocked by degradation of 
the sperm binding site. 
The nomenclature of ZP proteins in different mammals is complex (Harris et al. 2009; 
Conner et al. 2005). In this study, the ZP proteins are numbered from ZP1 to ZP4. This 
nomenclature is based on the molecular weight (Spargo 2002). For instance, ZP1 has the 
highest and ZP3 the lowest. ZP4 is paralogous gene of ZP1. The relationship to other ZP 
proteins is displayed in Table 2. 
A
ZP2
ZP1
ZP3
B C
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Table 2: Nomenclature of ZP Proteins. [1] Skinner et al. 1996; Harris et al. 2009; Spargo 2002. [2] 
Wardrip and Hedrick 1985; Yurewicz et al. 1987. [3] Dunbar et al. 1985; Harris et 
al. 2009. [4] Hasegawa et al. 1994. 
Modern 
nomenclature 
[1] 
Pig 
[2] 
Pig 
[3] 
Pig 
[4] 
Mouse Rabbit 
ZP1 ZPB1 - - - ZP1 - 
ZP2 ZPA ZP1/Mr 
82,000/90K  
(= 65K + 25K) 
ZP III ZP1 (= ZP2 + 
ZP4) 
ZP2 rc75 
ZP3 ZPC ZP3β ZP Ia ZP3β ZP3 rc45 
ZP4 ZPB2 ZP3α ZP II ZP3α - rc55 
 
The research group of Isojima / Koyama / Hasegawa (Hyogo, Japan) named the N-
terminus of porcine ZP2 (Ile36 – Ala168, P42099, uniprot.org) “ZP4” and the complete 
porcine ZP2 were designated as “ZP1”. 
Immunocontraception 
Since 1970, it is reported , that immunization with ZP proteins can reduce the fertility 
dramatically (Gwatkin et al. 1977; Sacco and Shivers 1973; Ownby and Shivers 1972; 
Shivers et al. 1972), without reacting on other tissues than the female reproduction organ 
(Palm et al. 1979). Two mechanisms could prevent fertilization after ZP vaccination (Figure 
2).  First, a humoral immune response, were ZP antibodies sterically mask sperm receptor 
and block contact between sperm and egg (Clydesdale et al. 2004; Barber and Fayrer-
Hosken 2000; Bagavant et al. 1993). This contraception last as long as antibody titer drops. 
Second, a cellular immune response, which leads to degeneration of the follicle pool or 
prohibits their development (Lloyd et al. 2010; Li et al. 2008; Curtis et al. 2007; Koyama et 
al. 2005; Lou and Tung 1993; Skinner et al. 1984). This reaction is permanent, because the 
number of follicles is finite. 
 
Figure 2: Schematic illustration of the immunocontraception mechanism induced by zona 
pellucida proteins. Vaccination with ZP can block sperm binding via antibodies or 
degradation of the follicles by macrophages. 
Whether a humoral or a cellular response is triggered could be managed by immune 
stimulants, like adjuvants (Brunner et al. 2010), cytokines or interleukins (Li et al. 2007). 
The immune stimulants support either transient or permanent spaying (Figure 2). A study 
Sperm Receptor
Fertilization             
ZP proteins/peptides
Vaccination             
Antibody against ZP
Autoimmune Reaction             
Blocking Sperm Contact
-Transient Spaying-
Zona Pellucida (ZP)
Folliclular Atresia
-Permanent Spaying-
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with porcine ZP3 in marmosets shows a follicular atresia with complete Freund’s 
adjuvants (CFA), but no atresia with sodium phthalyted lipopolysaccharide (SPLPS) 
(Upadhyay 1989).  
Even if a ZP antigen is able to prevent fertilization in one species or race, the success could 
vary due to the individual MHC genotype (MHC polymorphism) (Fitchen et al. 1995). That 
means not all individuals respond to the ZP immunization with a complete contraception, 
which is a drawback in the development of an immunocontraceptive for individual birth 
control (Gupta et al. 2014; Bagavant 1997). The response could also be a reduced 
offspring. For regulating populations of wild animals, not all individuals have to respond 
after ZP immunization (Naz and Saver 2016; Kirkpatrick et al. 2011; Chambers et al. 1997; 
Knipling and McGuire 1972). It is also enough to lower the fertility to a threshold, where 
birth and death rate is at least equilibrated. This threshold is species-specific and for wild 
mice a reduction of fertility of 60 % is deemed from experimental and modelled data 
(Hardy et al. 2002b; Chambers et al. 1997). 
Feral horses (Turner Jr. et al. 1997; Kirkpatrick et al. 1990; Liu et al. 1989), white-tailed 
deers (Naugle et al. 2002; McShea et al. 1997), elks (Shideler et al. 2001), bison (Duncan 
et al. 2013), grey seals (Brown et al. 1997) and elephants (Delsink et al. 2006) were 
regulated by immunizing with ZP proteins purified from pig ovaries (PZP). Porcine ZPs 
show the highest grade of cross reactivity among mammals, especially to ungulates (Frank 
et al. 2005), because of evolutionary conserved sequences. For example, 92.4 – 100 % 
contraception was achieved in a herd of wild horses in Maryland, USA over the time of 13 
years (Kirkpatrick and Turner 2008). Another study with captive animals shows a mean 
spaying effect of 93.8 % of 30 mammalian species (Frank et al. 2005). 
ZP-immunocontraception is a promising alternative to hunting, trapping or poisoning e.g. 
in reservation zones or urban areas is forbidden, socially unpopular or inhuman 
(Kirkpatrick et al. 2011; Barfield et al. 2006; Grandy and Rutberg 2001; Oogjes 1997).  
Recombinant ZP vaccines 
The limitation of porcine oocytes, the relatively high costs per dosis (30 $, treatment 
excluded) and a potential to cause inflammations due to the contamination with oocyte-
associated proteins which could push the development of recombinant vaccines (Naz and 
Saver 2016; Gupta et al. 2014; Kirkpatrick et al. 2011; Gupta 1997). Most of the them are 
composed of one of the four ZP proteins of various species and are expressed in E. coli 
(Gupta et al. 2013; Kitchener et al. 2009b; Lee et al. 1993), yeast (Lai 2004), insect cells 
(Hardy et al. 2003; Prasad et al. 1995)  or mammalian cells (Clydesdale et al. 2004; 
Martinez 2000; Tsubamoto et al. 1999; Paterson et al. 1998). The E. coli expressed bonnet 
monkey ZP2 dramatically reduced the fertility in bonnet monkeys (Govind et al. 2002). In 
New Zealand Koalas (Phascolarctos cinereus) (Kitchener et al. 2009b) and Eastern Grey 
Kangaroos (Marcopus giganteus) (Kitchener et al. 2009a) were regulated by immunization 
with recombinant brushtrail possum (Trichosurus vulpecula) ZP3. Whereas, in most of the 
cases PZP was shown to be much more immunogenic than recombinant peptides or 
proteins (Miller et al. 2013).  
To reach the market, recombinant ZP vaccines should feature a single application, long 
lasting protection and a new vaccine delivery system (Gupta and Minhas 2017; Gupta et 
al. 2011). Formulation for more effective delivery and strong adjuvant for immune 
14____Introduction  
 
stimulation are the key factors in this development, by using just as antigen design (Gupta 
et al. 2011). Live bacteria (Zhang 1997) and viruses (Lloyd et al. 2007; Jackson 1998) were 
used to express ZP antigens directly in the animal and reduce population size very cheaply, 
but caused safety concerns for humans and other non-target species (Angulo and Cooke 
2002). Another delivery approach is to entrap the antigen inside organic (e.g. lipid-based) 
or inorganic (polymer beads) particles to enable an ongoing vaccine release after dart gun 
injection (Garside et al. 2014; Gupta et al. 2011; Kanchan et al. 2009). Edible plant parts 
could be used for oral immunization delivered by a transmucosal carrier (Kwon and Daniell 
2016). Mucosal vaccination using a bait could be an promising approach (Naz 2005).  
Plant expression systems 
Genetically modified plants can be used as bioreactors to produce recombinant proteins 
or chemicals for medicinal and commercial purposes, like therapeutic products, 
nutritional components, vaccine antigens, biodegradable plastics and industrial products 
(Sharma and Sharma 2009). This strategy is called molecular farming (Franken et al. 1997). 
Human growth factor expressed 1986 in transgenic tobacco was the first important 
pharmaceutical (Ma et al. 2003; Barta et al. 1986). Many other relevant pharmaceuticals 
like therapeutic proteins (Shaaltiel et al. 2007), antibodies (Cox et al. 2006) and vaccines 
(Mason et al. 1992) were produced in different plant expression systems  (Yusibov et al. 
2014). Using plants for production has some advantages, but also associated with 
disadvantages which are described in the following paragraph. 
Advantages and disadvantages 
Recombinant expression of biopharmaceuticals in plants is generally cost effective, 
because it does not require expensive fermenters, culture media (Chen and Davis 2016) 
or skilled personnel for production process (Twyman et al. 2003) and uses well established 
processes of crop cultivation and storage (Giddings 2001). Depending on the yield, it is 
estimated that recombinant proteins can be produced in plants at 2 – 10 % of the cost of 
microbial fermentation systems and at 0.1 % of the cost of mammalian cell cultures 
(Twyman et al. 2003; Giddings 2001). Downstream processing accounts for the most of 
the cost of the production (Obembe et al. 2011; Twyman et al. 2003; Evangelista et al. 
1998) and when a high purity is required, all recombinant protein expression systems have 
similar cost of production (Twyman et al. 2003).  
The production in plants is advantageous, when the pharmaceutical can be used in partly 
processed or unprocessed form, which could save the cost of downstream processing 
(Twyman et al. 2003). For example, the hepatitis b surface antigen produced in transgenic 
tobacco elicited a similar antibody response after injection as the commercial equivalent 
from yeast, but without expensive downstream processing by Ni-NTA chromatography 
(Thanavala et al. 1995). Saving in costs increases once more, when unpurified 
pharmaceuticals can be used without formulation, e.g. oral vaccines (Topp et al. 2016; 
Xiao et al. 2016) Plant material of the production host plant can be used for encapsulation 
of the vaccine on one hand and can boost the immune response on the other hand (Bosch 
and Schots 2010). The costs for a refreshment polio protection was dramatically reduced 
by a plant-based, “bioencapsulated”, oral polio vaccine (Daniell et al. 2016).   
A premise for no or minimal purification of the pharmaceutical is lack of animal 
pathogens. Since animal pathogens not hosting in plants or are able to propagate (Buyel 
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and Fischer 2012; Commandeur et al. 2003; Streatfield and Howard 2003), this biosafety 
aspect is given, but no contaminations with mycotoxins, pesticides, herbicides and 
harmful endogenous plant secondary metabolites must be ensured (Doran 2000).  
A further advantage of the plant-based production is the easy and fast scalability process, 
which reacts faster on market demand (Davies 2010). The production capacity can be 
modulated by using more or less land (Twyman et al. 2003). Furthermore stable and 
relatively cheap storage of recombinant proteins in plant tissue enables a cold-chain free 
and long-lasting storage (Twyman et al. 2005; Walmsley et al. 2003). Producing 
pharmaceuticals on the field includes concerns of horizontal gene transfer to other crops 
and wild-type plants. The isolation of the transgenes could be realized by geographical 
isolation, buffer plants, appropriate biological containment, like maternal inheritance or 
male sterility, and cultivation in a glasshouse (Daniell et al. 2009; Rigano and Walmsley 
2005). Although cultivation in a glasshouse may limit the scalability and increases costs, it 
offers stable growing conditions and high containment (Mikschofsky and Broer 2012; Ma 
et al. 2003) and might comply regulatory requirements (Stöger et al. 2002). 
Another benefit of the plant expression system is the glycosylation. Compared to yeast 
and insects, plant N-Glycosylation is much more similar to mammalian glycosylation, 
nevertheless plants add specific xylose and fucose residues that are not present in animals 
(Loos and Steinkellner 2014; Faye et al. 2005b). This fact could increase immunogenicity 
(Bosch and Schots 2010; Matoba et al. 2009; Bardor et al. 2003a; van Ree and Aalberse 
1999; Kurosaka et al. 1991), but involves an individual testing of the plant-derived 
pharmaceutical to allergic reactions (Bardor et al. 2003a). Although post-translational 
modifications are slightly different, protein synthesis pathway is conserved between 
plants and animals, which makes plant-made mammalian proteins appear to fold and 
assemble correctly (Twyman et al. 2003).  
Choice of production platform 
To the high effective production of a pharmaceutical an appropriate plant transformation 
strategy (stable nuclear, cell suspension, transient expression system) and the suitable 
plant host is important (Obembe et al. 2011). These two factors determine together the 
accumulation level, the scalability, the storability, the costs and how the medication is 
administrated.   
Stable nuclear transformation includes the integration of the transgene in the plant 
genome, which is inherited to the next generations. When used in whole land plants, it 
provide the highest scalability and lowest production cost in comparison to the other 
plant transformation strategies (Xu et al. 2012). This strategy accumulates the 
recombinant protein depending from the promoter in all plant cells or in specific tissues, 
like seeds. The CaMV35S promoter is known as a strong constitutive promoter (Seternes 
et al. 2016; Odell et al. 1985) and is often chosen for high expression in plants (Twyman 
et al. 2003). The finite shelf life of the tissue, like leaves and cell suspension makes a 
subsequent processing mandatory (Xu et al. 2012), but after freeze-drying many 
biopharmaceuticals show a high stability for months (Chan and Daniell 2015). The 
seed-specific expression in transgenic plants can be achieved by the arcelin5-I promoter 
from Phaseolus vulgaris (Goossens et al. 1994). Although CaMV35S expresses the 
transcript in leaves and seeds, CaMV35S seems to have a lower activity in seeds than in 
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leaves (Boothe et al. 2010). The use of a seed-specific promoter may improve the 
accumulation level (Jaeger et al. 2002; Fiedler et al. 1997). According to van 
Droogenbroeck et al. 2007 only 0.003 – 0.005 g Arabidopsis seeds are required to gain 
100 µg scFv-Fc, expressed under the control of the phaseolin promoter (Sengupta-
Gopalan et al. 1985). With the unknown seed protein (USP) (Bassüner et al. 1988) and the 
legumin B4 (leB4) (Bäumlein et al. 1986) promoter Scheller et al. 2006 expressed 0.5 % of 
TSP transgenic scFv antibody in transgenic tobacco seeds and increased this amount 40-
times by fusing C-terminally 100 iterations of the elastin like binding (ELP) domains. The 
reason for seed-based production is the advantages over leaf-based production. Plant 
seeds are designed for the synthesis and long-term storage of proteins, which may 
account for 8 – 40 % of their weight (Hernández et al. 2013). With this feature, they are 
able to store heterologous proteins in high concentration in a small volume without 
further processing until use (Twyman et al. 2005; Stöger et al. 2005). In case of purification 
a reduced number of residing proteins in seeds, could lower the cost for fewer processing 
steps (Twyman et al. 2005; Jaeger et al. 2002). 
Transient expression system mediated by a plant binary vector initiates the expression of 
a viral replicon and allows rapid protein production within a few days (Xu et al. 2012). 
Several plant viruses are used, like tobacco mosaic virus (TMV), cowpea mosaic virus 
(CPMV), potato virus (PVX), alfalfa mosaic virus and plum pox virus (Takeyama et al. 2015). 
This is typically carried out in N. benthamiana leaves, but it was also shown to work in 
other Nicotiana species, potato, green pea, Arabidopsis and lettuce (Xu et al. 2012). With 
the cr-TMV / TVCV-based MagnICON™ system (Icon Genetics, Halle) it is possible to 
produce 5 mg GFP per gramm fresh leaf in N. benthamiana in 14 days (Marillonnet et al. 
2004). This short-term availability of heterologous proteins is advantageous when sudden 
demand appears. The need of vacuum infiltration equipment combined with a mandatory 
processing makes this approach more cost intensive than the stable nuclear expression.  
The host defines total biomass yield, storage properties, cultivation costs, length of 
production cycle, cost of downstream processing and edibility (Obembe et al. 2011; 
Benchabane et al. 2008).  
Tobacco has a high soluble protein level, a high biomass yield of up to 100 tons of leaf 
biomass per hectare and as a model organism a variety of well-established transformation 
protocols (Tremblay et al. 2010). Due to the natural toxic alkaloids in the leaves, tobacco 
is not considered as food plant and therefore can not be able to breed with food-chain 
plants (Obembe et al. 2011). Tobacco is a good example, for the host defines the drug 
delivery way. The expression of pharmaceuticals in tobacco leaves normally makes 
purification necessary and only allows an administration via injection. An oral application 
of tobacco leaf material seems possible by using genetically modified tobacco variants 
(Menassa et al. 2001), with a very low nicotine concentration like cultivar MD609, which 
contains almost no nicotine (Kim et al. 2010). Due to the low level of toxic compounds, 
accumulation of the therapeutics in the seeds is another way to enable oral delivery with 
tobacco (Rossi et al. 2013). 
Seeds such as those of legumes are known to store much protein (up to 40 % of their dry 
weight (Lau and Sun 2009) and are highly suitable for the recombinant production of 
proteins (Mikschofsky and Broer 2012). One of them is pea, wich is independent from 
nitrogen fertilization and also has a high protein yield of approx. 25 % 
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(www.grainscanada.gc.ca). Because of the capacity to store high amounts of recombinant 
proteins and a high seed yield per hectar, the pea seed is suitable to produce 
pharmaceuticals (Mikschofsky and Broer 2012; Stöger et al. 2005). Pea is a leguminous 
plant and therefore acts as a self-fertilizer. An outcrossing of transgenes, under field 
conditions was not observed (Polowick et al. 2002). To increase the level of containment 
and yield, Mikschofsky and Broer 2012 recommend the cultivation of plants in the 
greenhouse chambers.  
Plant suspension culture is an alternative system of recombinant protein production 
compared to transient expression and stable nuclear transformation. Carrot cells are a 
capable platform for biopharmaceuticals, because of the relatively simple callus initiation 
and maintenance using stem segments, cotyledons, or roots as explants, as well as the 
high regeneration potential by either organogenesis or embryogenesis. These properties 
made carrot a model species suitable to study a number of processes such as 
morphogenesis, somatic embryogenesis, somaclonal variation, and protoplast recovery 
(Rosales-Mendoza and Tello-Olea 2015). There is the opportunity to establish a 
suspension culture, which offers full containment of the transgene and a high rate of cell 
growth combined with product uniformity (Shaaltiel et al. 2007). Protalix approved the 
first plant-based pharmaceutical, the glucocerebrosidase (GCD) which is lacking in 
patients with Gaucher´s disease. Due to non-existence of toxic compounds an oral 
vaccination is possible.  
Yield improvements 
Yield (mg/kg biomass) is a critical point for the success of a vaccine and will be determined 
by the host, the expression organ, the used promoter and the expression/transformation 
strategy as mentioned in the chapter before. But also expression itself and protein 
stability are factors influencing the yield (Schillberg et al. 2005; Faye et al. 2005a). 
The expression of a heterologous protein is regulated at transcriptional, translational and 
post-translational level (e.g. glycosylation) (Desai et al. 2010). The transcriptional level 
includes copy number and integration locus, initiation of transcription, RNA processing 
and RNA stability (Desai et al. 2010). Optimal transgene copy number and integration 
locus is difficult to control and could achieved by selecting best performing lines from a 
population of transgenic plants. But with an appropriate design of the expression cassette 
the promoter activity, RNA processing (e.g. integration of intron-mediated 
enhancements), RNA stability (e.g. polyadenylation sites), translational efficiency (e.g. 
codon usage can influence the transcriptional and translational level and influence the 
expression rate (Desai et al. 2010; Schillberg et al. 2003; Stöger et al. 2002). 
Protein stability is mainly influenced by numerous proteolytic processes inside the plant 
cell (Benchabane et al. 2008). Localizing the transcript to a cell organelle, compartment 
or tissue could lower the risk of degradation, because of lower abundance of residing 
proteases or lower activity due to desiccant conditions (Xu et al. 2012; Benchabane et al. 
2008; Petruccelli et al. 2006; Ma et al. 2003). Co-expression of protease inhibitors, 
chaperons or fusion partners could enhance the protein stability (Benchabane et al. 2008; 
Mishra et al. 2006). A rapid expression via transient expression systems (e.g. MagnICON) 
could also shorten the time of contact between a heterologous protein and host proteases 
(Nausch et al. 2012a).  
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For molecular farming in plants a high accumulation of the pharmaceutical is necessary. 
Accumulation of recombinant proteins in plants often results in much lower accumulation 
levels than 1 % of TSP (Daniell et al. 2001), what often is a reason for not realizing a market 
launch (Desai et al. 2010). The optimal production platform has to be determined 
experimentally and subsequent yield improvements are often necessary.  
Plant-based ZP spaying  
The idea of using plants to express ZP vaccines for spaying animals is a traditional 
approach. Fitchen et al. 1995 expressed virus-like particles (VLP) containing a 
contraceptive murine ZP3 peptide (aa 331-343) (Millar et al. 1989). This protein was 
robust and accumulated in high levels as a rod-like particle in tobacco. Parenteral 
immunization of BALB/c mice exhibited a relatively low level of anti-ZP3 antibodies and 
exhibited no significant effect on mice fecundity. The reason for using plants as 
production platform are the high scalability and  cheap production, which provide a 
virtually universal access of bulk protein (Fitchen et al. 1995). Furthermore they offer oral 
delivery, when ZP vaccine is accumulated in edible plant parts (Polkinghorne et al. 2005; 
Smith et al. 1997). Transgenic tomato accumulated 37.8 µg/gDW of a heat-labile 
enterotoxin B subunit (LTB) / murine ZP3 fusion protein of (Walmsley et al. 2003) and 
achieved a reduction of 45 % of mice litter size after oral immunization (Patent application 
WO2002083072A2, example 20). 
If a mammalian-like glycosylation pattern for ZP vaccines is essential or at least 
supportive, plants could offer this feature. But the influence of glycosylation at the ZP 
glycoproteins is contentious, because the literature shows different results. A 
glycosylation of the native ZP3 gained from pig ovaries (Paterson and Aitken 1990) or 
expressed in a baculovirus expression system (Prasad et al. 1995) leads to a higher and 
enzymatically or chemically de-glycosylated ones to a lower immunogenicity (Kerr 1999; 
Keenan 1991; Bhatnagar et al. 1991; Yurewicz et al. 1987; Sacco et al. 1986). Recombinant 
expression of rabbit ZP1 (VandeVoort et al. 1995; Schwoebel 1992), bonnet monkey ZP3 
(Kaul et al. 1997) and ZP1 (Gupta 1997) in a bacterial expression with no glycosylation is 
only poor immunogenic (Paterson et al. 1998). However, some E. coli produced vaccines 
had strong contraceptive effects (see above: “Recombinant ZP vaccines”). According to 
Hasegawa et al. 2002 the immunocontraceptive efficacy of the ZP antibody raised against 
the ZP vaccine mainly depends on high similarity to the target on the ZP, so a 
mammalian-like glycosylation could be important for spaying, when the target ZP epitope 
is also natively glycosylated (Hardy et al. 2003).  
The creation of spaying vaccines in food-chain plants or edible plant organs makes a 
closed production environment necessary. The breeding in greenhouses complies this 
requirement (Ma et al. 2003), although the scalability is more limited than open field 
cultivation. A second approach is the production in a cell culture, like carrot cell 
suspension, which also offers full biocontainment of the transgene (Rosales-Mendoza and 
Tello-Olea 2015). 
However, every new transgenic approach needs a case specific study. For a spaying 
vaccine, both questions of species-specificity and risk assessment of transgenic outbreak 
(dependent of host and cultivation system) into other edible plants have to rule out.  
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Aims  
The main aim of this study is to choose an antigen for spaying different animal species 
and to design a potently immunogenic vaccine in plants. The novel designed vaccine will 
be expressed in different stable and transient plant expression systems to find the optimal 
production platform. Based on the assumption, vaccine efficacy is independent from 
production system, the vaccine will be produced by the system with the highest 
production rate, comprising of yield per biomass and production time, to test this in a 
rodent model. In these animal trials antibody titer development and effect on fecundity 
will be determined. Due to the determined results from production (accumulation level) 
and efficacy (spaying) site an economic evaluation will be possible. 
The aims of the current study are as follows: 
1. Designing a ZP vaccine in fusion with adjuvants. 
a. Selecting optimal ZP antigens with high potential of spaying. 
b. Designing a vaccine, which is expressible in plants and will elicit immune 
response, with the possibility of oral vaccination 
2. Transient and stable expression in different transgenic plant systems 
a. Cloning transformation vectors 
b. Agrobacterium-mediated plant cell transformation 
3. Detection of ZP fusion protein / ZP vaccine 
a. Protein isolation  
b. Quantitative determination of accumulated ZP vaccine via ELISA 
c. Qualitative assessment of ZP vaccine via Western blot analysis 
4. Purification of ZP vaccine proteins 
a. Small scale purification via affinity chromatography 
b. Select vaccine production platform by yield/time and vaccine 
concentration/biomass 
c. Upscaling with results from vaccine characterization (point 5) 
5. Biochemical characterization of ZP vaccine 
a. Vaccine stability in vivo & in vitro 
6. Evaluation of efficacy  
a. Testing potential to elicit immune response  
b. Testing the immunocontraceptive effect 
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3. Material & Methods 
3.1 Vector construction and cloning 
DNA isolation 
To isolate plasmid DNA from E. coli, NucleoSPin® Plasmid EasyPure (Macherey-Nagel) 
protocol was used. DNA mass was measured by Nanodrop at 260 nm. 
Plant DNA was isolated (Murray and Thompson 1980) using the Khanuja buffer (Khanuja 
et al. 1999). Leaf sample (2 cm2) was homogenized in a bead mill (Precellyse, Bertin 
Instru.) and 300 µl Khanuja buffer running 2 x 30 sec with 6,500 rpm. Homogenate was 
incubated for 30 min at 65 °C. 300 µl Chlorophorm: Isoamylalcohol (24:1) were added in 
the samples and overhead rotated for 1 min. Samples were centrifuged for 5 min at 
13,000 rpm at 4 °C. Aqueous phase was transferred to a new Eppendorf tube and gently 
mixed with 1 volume of isopropyl alcohol. DNA was precipitated for 30 min in a freezer 
and pelleted by spinning at 13,000 rpm for 15 min at 4 °C. Supernatant was discarded and 
pellet was washed with 200 µl 70 % ice cooled ethanol. Pellet was air dried and 
resuspended in 30 – 50 µl ddH2O. 
Transformation of bacteria 
E. coli TG1 and BL21 were transformed via heat shock method (Hanahan 1983). 
Competent cells were thawned 30 min on ice. Up to 10 µl Plasmid-DNA solution was 
added. Heat shock was 2 min on 42 °C with subsequent cooling for 5 min on ice. After 
addition of 1 ml LB Medium, cells were incubated at 37 °C for 1 h on a shaker. Postively 
transformed cells were selected on LB plates containing antibiotics.    
A. tumefaciens ICF320, LBA 4404, EHA 105 were transformed via freeze shock method. 
Bacteria were grown over night in LB media. After addition of 10 µl DNA to 500 µl bacteria 
suspension, mixture was kept on ice for 5 min. Subsequently it was frozen for 5 min in 
liquid nitrogen and thawn for 5 min at 37 °C on a shaker after adding 1 ml LB media. Cells 
were grown for 4 h at RT. Positively transformed bacteria were selected on agarose plates 
containing antibiotics.    
Colony-PCR 
To identify positive E. coli clones, each single colonies were picked with a wooden, steril 
toothpick and boiled for 5 min in ddH2O. 1 µl was used in a PCR as template. For testing 
A. tumefaciens clones were boiled in 50 µl lysis buffer (0.05 M NaOH + 0.25 % SDS), cooled 
on ice. After addition of 450 µl ddH2O, cell debris was pelleted by centrifugation. 1 µl of 
supernatent was used as template in a colony PCR (Table 7). 
DNA digestion and ligation 
To identify a plasmid by characteristic fragments after enzymatic digestion, 1 – 5 µg DNA 
was used with 0.5 µl enzyme. Batch was incubated for 1.5 h at 37 °C. Restriction pattern 
was checked in an agarose gel electrophoresis. 
For a subsequent batch ligation, the amount [fmol] of vector and insert was determined 
with the aid of nanodrop (Thermo Fisher™). The ratio between vector and insert was 1:1 
till 1:5. Approach was incubated for 1.5 h at 37 °C and enzymatic reaction was stopped by 
10 min at 65 °C or higher, dependent of enzyme. Ligation was performed with T4 ligase 
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(Thermo Fisher™) overnight in the fridge. T4 Ligase was deactivated by 65 °C incubation 
for 10 min. 
When linearized vector and insert have to be purified by gel electrophoresis, QIAquick 
PCR Purification Kit was used to extract the bands from the agarose gel. 
VacZP2 
The fusion gene was synthesized by Eurofins (Ebersberg, Germany) and delivered in a 
pUC57 vector. The fusion gene vacZP2 (Figure 4D) was inserted into binary transformation 
vectors pSingle35S (Figure 4A) and pARC (Figure 4B) by XmaI and SmaI restriction sites 
(Figure 6A, B). To obtain seed specific expression the vector pARC was cloned by Antje 
Höhne (unpublished data), a pLH9000 (Hausmann and Töpfer 1999) derivate, carrying a 
seed specific arcelin5-I promoter from Phaseolus vulgaris (Jaeger et al. 2002; accession 
#AF458478). For transient expression we cloned the fusion gene via BsaI sites Engler et 
al. 2008; Figure 6) in the cr-TMV / TVCV-based MagnICON™ vector pICH29912 (Figure 4C), 
which was kindly provided by Nomad Bioscience (Halle/Saale, Germany). 
ZP2onlyP 
The coding region of pZP2 was amplified via recombinant PCR from a pET28a + vacZP2 
vector with the primer pZP2_pICH31120f and pZP2_pICH31120r (Table 9). The PCR 
product was cloned into a pJET1.2 vector (CloneJET PCR Cloning Kit, Thermo Fisher; Figure 
12). The coding region of pZP2 was combined with SEKDEL and histidine tag (Figure 4E) 
by BsaI restriction into pICH31120 (Figure 4F), a transient expression vector (Nomad 
Bioscience, Halle), and transformed to Agrobacterium tumefaciens strain ICF320. 
VacZP3-P 
To amplificate vacZP3-P PCR program 2 was conducted (Table 6). PCR product vacZP3-P 
(Figure 14) was cloned blunt end with CloneJet-Kit (Thermo Fischer™) into pJET1.2. 
VacZP3-B 
For expression in E. coli we deleted the ER-targeting signal by PCR with primer 
ÜEx_synZP3_NdeI and ÜEx_synZP3_XhoI (Table 9) and integrated the product in vector 
pJET1.2 by blunt end cloning (Figure 20). VacZP3-B was cloned into pET28a by NdeI and 
XhoI restriction sites and selected by kanamycin. VacZP3-B was integrated into the 
transformation vector pET22b by NdeI and XhoI restriction sites and transformed into E. 
coli BL21. Clones were selected by ampicillin. Transformation vector is an isopropyl β-D-1-
thiogalactopyranoside (IPTG) -inducible overexpression vector (Novagen). The integrity 
was validated by sequencing (Eurofins MWG, Ebersberg, Germany).  
3.2 Stable transformation & cultivation 
Carrot cell 
For the experiments a callus culture of petioles of Daucus carrota (var. Rotin) made by 
Jafargholi Imani (University Giessen) was used. Suspension cell culture was established as 
described by Mikschofsky et al. 2009c with B5 media (Gamborg et al. 1968) instead of 
Litvay’s medium. Suspension cell transformation was performed with Agrobacterium 
tumefaciens strain LBA4404 described by Mikschofsky et al. 2009c. After transformation 
a homogeneous and friable callus material light, yellow in color, was placed in a thin layer 
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on solid Gamborg B5 with 0.47% (w/v) Gamborg B5 medium (incl. vitamins), 2% (w/v) 
sucrose, 0.6% (w/v) agarose, 2.3 μM 2.4-D, 50 µg mL-1 kanamycin and 250 µg mL-1 
cefotaxime for selection of transformed callus cells. After a growth period of approximatly 
four weeks in growing chambers at 24/18°C under dark conditions, small single transgenic 
callus clusters where transferred onto a new plate. 
Tobacco 
The vectors p35S-VacZP2 (Figure 4A), pARC-VacZP2 (Figure 4B) and pARC-VacZP3-P 
(Figure 5A) were introduced into tobacco Nicotiana tabacum cv. Petit Havana SR1 (Maliga 
et al. 1973) by the Agrobacterium tumefaciens strain LBA4404 conducted as previously 
described (Wohlleben et al. 1988). Regenerated plants were set on soil and cultivated in 
greenhouse until they mature. 
Pea 
Transformation of Pisum sativum cv. Greenfeast with pARC-VacZP3-P (Figure 5A) and 
cultivation of pea was conducted as described in Mikschofsky et al. 2009b initially 
described by Polowick et al. 2000. Minor adaptations of the Mikschofsky protocol were 
carried out. Cultivation media P1, P2, P3 (alias B5/2T) contained no L-phosphinothricin 
(L-PPT). Shoot elongation medium (MS7T, Polowick et al. 2000) was not used. Agarose 
concentration in P3 medium was reduced to 1.5 % (w/v). 
E. coli 
After transforming pET-VacZP3-B (Figure 5D) to E. coli BL21 bacteria were cultivated and 
IPTG-induced like previously described by Nausch and Broer 2016b. Pellet was stored 
at -80 °C for further processing. 
3.3 Transient tobacco transformation 
Seven to nine weeks old N. benthamiana plants transfected with pICH-VacZP2 (Figure 4C), 
pICH-∆ZP2onlyP (Figure 4F) and pICH-VacZP3-P (Figure 5C) according to Ponndorf et al. 2016 
with minor adaptations, respectively. In our method the atmosphere under the cabin´s 
hood after evacuation was gradually restored within 5 minutes.  
Leaves were snap-frozen with liquid nitrogen directly after harvest and stored at -80 °C. 
Frozen leaves were freeze-dried for three till five days. Isogenic leaves (same day of 
harvest) were pooled and pulverized using a blender. Material was stored at room 
temperature (RT) in the dark. 
3.4 Protein isolation 
Carrot calli 
200 mg calli was homogenized in a bead mill (3 x 30 sec, 6300 rpm, 5 min cooling pause 
between each round) with 250 µl 1x PBS (10 mM Na2HPO4, pH 7.4, 2 mM KH2PO4, 137 mM 
NaCl, 2.7 mM KCl), sea sand and zirconia beads. Protein extract was obtained by spinning 
3 times for 5 min at 15000 xg and 4 °C. 
Tobacco 
Fresh leaf material was ground by an Eppendorf tube pestle cooled in liquid nitrogen. 
Freeze-dried plant material was pulverized by a blender. Tobacco seed material was 
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homogenized in cooled protein extraction buffer by a ceramic bead mill (Precellyse, VWR, 
Darmstadt, Germany). After addition of 500 µl protein extraction buffer (50 mM NaH2PO4, 
250 mM sucrose, 300 mM NaCl, 5 mM Imidazol) to i) 100 – 150 mg fresh material ii) 23 – 
30 mg freeze-dried or iii) 50 mg tobacco seeds, samples were mixed for at least half a 
minute and subsequently centrifuged (5 min, 15000 xg) 3-times at 4 °C. Total soluble 
protein (TSP) content of supernatant was determined by Bradford 1976 method using 
Coomassie  and bovine serum albumin as standard. 
Pea 
Sample material from dry pea seeds was obtained by milling cotyledons with a mini-drill 
(Dremel, US-WI) (Figure 3). Care was taken to not damage the embryo. Resulting milling 
dust was collected in 1.5 ml Eppendorf tubes and cold protein extraction buffer was 
added. Sample was vigorously shaken for 10 min and 3 times centrifuged (5min, 15,000 
xg) at 4 °C. TSP in supernatant was determined by (Bradford 1976) method using 
Coomassie  and bovine serum albumin as standard.  
 
Figure 3: Milled sample from pea cotyledons using a mini-drill. 
3.5 Ni-NTA purification 
Plant 
Freeze-dried leaf material was mixed with protein extraction buffer by vortexing or using 
a blender (Polytron Pt-MR 2100, Kinematica AG, Switzerland). The supernatant was 
loaded via a Perista Mini Pump SJ-1215 (Burkhard Instrumente AG; Zürich / Bional AG) at 
2.5 ml min-1 on a column (Biorad™, Prod# 727-1517) containing 5 ml of pre-equilibrated 
Ni-NTA resin (Probond™ resin, Prod# 46-0019, Life Technologies). The resin was washed 
with 100 ml of wash buffer (50 mM NaH2PO4, 10 mM imidazol, 300 mM NaCl, pH 8) at 2.5 
ml min-1. To wash the bound protein from the column 20 ml elution buffer (50 mM 
NaH2PO4, 300 mM imidazol, 300 mM NaCl, pH 8) was added with a reduced flow rate of 1 
ml min-1. The elution fraction was concentrated and desalted in a Vivaspin 20 (GE 
healthcare, Freiburg, Germany, membrane cutoff: 10 kDa, Prod# 28932360) ultrafiltration 
falcon by spinning at 4600 rpm in a swing-out centrifuge (Heraeus multifuge 3 L-R, Hanau, 
Germany). The sample was concentrated to a volume of 2 -5 ml and refilled to 20 ml with 
cooled PBS buffer. This procedure was done two times at 4 °C. 
E. coli 
Protocol for purification of TT-KK-ZP3 was provided by Vidisha Minhas (PhD student of S. 
K. Gupta; Dehli). After resuspending the pellet in binding buffer (20 mM NaH2PO4, 500 
mM NaCl, 20 mM Imidazole, 8 M urea, pH 8), cells were lysed by sonication (8 x 30 sec; 
40 W). Cell suspension was rotated for 2 hours by an over-head rotator. After spinning 
(10,000 xg; 20 min; 4 °C) supernatant was collected and incubated on an over-head 
rotator with Ni-NTA resin for 3 h. Mixture was loaded on an equilibrated BioRad® Poly-
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Prep column. Column was washed twice with 4 ml washing buffer (20 mM NaH2PO4, 500 
mM NaCl, 40 mM Imidazole, 8 M urea, pH 6.3). Protein was eluted 4 times with 0.5 ml of 
elution buffer (20 mM NaH2PO4, 500 mM NaCl, 250 mM Imidazole, 8 M urea, pH 4.5). 
Fraction with highest heterologous protein was dialyzed against renaturation buffer (20 
mM PBS, 0.1 mM glutathione (GSH), 0.01 mM glutathione disulfide (GSSG), 1 mM EDTA, 
10 % sucrose, 4 M urea, pH 8) for 2 h. Buffer was refreshed with gradual reduction of urea 
concentration (2, 1, 0.5 M). Final buffer was 20 mM PBS burfer (20 mM NaH2PO4, 2 mM 
KH2PO4, 137 mM NaCl, 2.7 mM KCl). Sample was stored at -20 °C until use. 
For purification of VacZP3-B bacterial pellet was resuspended in lysis buffer (50 mM Tris-
KCl, 300 mM NaCl, 10 mM Imidazole, pH 8) and cells were destroyed by 3-times sonication 
(Bandelin Sonotrode HD2200 + micro tip MS73) for 30 sec at 10 % power. Between the 
interval tip was cooled down. Cell debris was separated by 15 min at 4,600 xg and 1 h at 
16,000 xg subsequent spinning. Supernatant was loaded on an equilibrated Ni-NTA 
column and washed with 10 resin-volumes of buffer I (like lysis buffer but 20 mM 
Imidazole) and buffer II (like buffer I but 75 mM imidazole). VacZP3-B was eluted with 2 
resin-volumes of elution buffer (like lysis buffer but 300 mM imidazole). Buffer was 
exchange by ultrafiltration (Vivaspin 20, 30 kDa cut-off, Satorius) to 1x PBS (pH 7.2). 
3.6 Enzyme-linked immunosorbent assay (ELISA) 
Anti-CTB & GM1 
Content of CTB and assembling to pentamers was determined by anti-CTB ELISA and 
GM1-ELISA (Mikschofsky et al. 2009b). 
Anti-VacZP2 & anti-ZP2onlyP 
Serum IgG against VacZP2 was determined by coating VacZP2 and pZP2onlyP to microtiter 
plates (detailed information in Supplement). Secondary Antibodies were anti-Mouse-IgG 
conjugated to horseradish peroxidase (HPR).  
Anti-VacZP3-P & anti-TT-KK-ZP3 
This ELISA was used to detect anti-VacZP3-P antibodies in blood serum. VacZP3-P was 
diluted in 1x PBS to 100 ng/ml and loaded to 96-well microtiter plate 100 µl each well. 
After incubation for 2 h at 37 °C wells were washed 3-times with 200 µl PBS + 0.5 % 
Tween20. Blocking step was conducted with 300 µl 1 % BSA in 1x PBS for 45 min at room 
temperature (RT) on a shaker. After washing step animal serum diluted to i) 1:6,000 in 
KVP (Konjugatverdünnungspuffer, DRG Instruments GmbH, Marburg) for anti-VacZP3-P 
ELISA and ii) to 1:500 in KVP for anti-TT-KK-ZP3 ELISA, respectively. Diluted sera were 
loaded and incubated for 1.5 h at RT on a shaker. After washing step anti-mouse-POD 
antibody (1:2000 in KVP) was incubated for 45 min at RT on a shaker. After washing step 
100 µl 3,3′,5,5′-Tetramethylbenzidine (TMB) was loaded for 3 min and stopped with 250 
mM H2SO4. Detection was done at 450 nm. 
3.7 Western blot analysis 
Protein extracts were separated in an 12 % SDS-PAGE (Ponndorf et al. 2017) with the 
adaptation of 10 minutes of heat denaturation and transferring the proteins by tank 
blotting (BioRad, Hercules, USA) (100 V, 40 min) to the membrane. To detect the N-
terminal CTB domain the membrane was blocked with 4 % skim milk (w/v) in TBST (20 
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mM Tris, 137 mM NaCl, 0.05% Tween20, pH 7.6) for 1.5 h at room temperature (RT). 
Primary anti-CTB antibody (Fizgerald, 20-CR18) was diluted 1:2,000 in buffer II (2 % skim 
milk (w/v) in TBST) and incubated for 2 h. After washing with buffer II, secondary antibody 
anti-goat-IgG, diluted 1:5,000 in buffer II was incubated for 1 h. Membrane was washed 
with TBS (20 mM Tris, 137 mM NaCl, pH 7.6) and ECL was done. Anti-histidine and 
concanavalin A Western blot analysis was conducted as (Nausch and Broer 2016b) with 
minor adaptations, including membrane for anti-histidine detection was blocked with 3 % 
skim milk (w/v) in TBST. 
3.8 Degradation assay 
VacZP2 was extracted with optional addition of protease inhibitor (cOmplete, Roche, 
4693124001). The TSP extract was incubated at RT and 4 °C, respectively. Incubation was 
stopped by addition of SDS containing sample buffer and boiled for 10 min. Samples were 
loaded on 12 % SDS-PAGE and blotted on a nitrocellulose membrane. Subsequently, an 
anti-CTB Western blot was conducted. 
3.9 Densitometric CTB determination 
CTB was detected using an anti-CTB Western blot with gradual dilutions of a CTB standard 
(Sigma-Aldrich) and VacZP2 after purification. The film with medium signal strength was 
captured by a digital camera (Nikon E4500) in front of a white paper. The distance of the 
film and the paper was 20 cm to allow transillumination. The density of the CTB standards 
(50, 100, 300 ng) was compared to the density of the CTB monomer signal in the vaccine 
with ImageJ (Abràmoff et al. 2004). The estimated mass of CTB was related to the total 
loaded mass of CTB within the VacZP2 lane, which was previously determined in the anti-
CTB ELISA.  
3.10 Northern blot analysis 
RNA isolation and Northern blot analysis was conducted described by Ponndorf et al. 
2016. Dig-labeled CTB specific probe was amplified by Primer CTB_new_fw and 
CTB_new_rev (Table 9). 
3.11 Animal trial 
VacZP2 
Four test groups of female FvB/J mice were primed subcutaneous with 264 µg (140 µl) 
purified VacZP2 in 1x PBS (pH 7.2) or the equal volume 1x PBS with or without 10 % 
Polygen (MVP Lab). All mice were boostered intraperitoneal with the same dose after 26 
and 51 days. During this immunization schedule the animals were retrobulbary bleeded 
on day 0, 21, 37 and 65 (Figure 30C).  
Two groups of 8 female golden hamsters were primed with 20 µg (200 µl) VacZP2 and the 
same volume of 1x PBS, respectively. All doses included 10 % Polygen (MVP Lab). After 
21, 35, 49, 63 days animals were boostered with the same doses. The animals were bleed 
on day 0, 21, 35, 49, 63 and 84 (Figure 31C). One animal per group were euthanized and 
ovariectomized on day 21 and 49. After 42 days 4 and 5 females immunized with and 
without VacZP2 were mated with male hamsters with proven fertility, respectively. On 
day 84 two VacZP2 immunized animals and 1 animal from the PBS group were euthanized 
and ovariectomized.  The ovaries were fixated in 4 % formaldehyde and embedded in 
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paraffin wax. Tissue sections (5 µm) were stained with hämatoxylin/eosin using standard 
protocols. 
VacZP3-P 
Three groups of ten female BALB/c mice were subcutaneously primed with two, seven 
and 21 µg plant-made VacZP3-P, respectively. One group was vaccinated with 25 µg 
TT-KK-ZP3, a bacterial vaccine with proven sterilizing efficacy (Gupta et al. 2013), to verify 
responsiveness of the BALB/c mouse strain. One group received 1x PBS (pH 7.2). All doses 
included 10 % Polygen (v/v) (MVP Lab). At day 43 and 63 all animals were subcutaneously 
boostered with the same doses received for priming. Animals were retrobulbary bled 
once before and three times after each treatment at day 0, 41, 58 and 72. After 82 days 
females were mated with males of proven fertility. For an overview see Figure 37C. 
3.12 Statistics 
To identify a significant difference between tested groups (p ≤ 0.05), data were analyzed 
either in an univariant ANOVA (including post-hoc Tukey-HSD) or with a non-parametric 
test (Mann-Whitney-U) with SPSS (IBM, Version 22). 
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4. Results 
4.1 Gene design and expression strategy 
We designed two fusion vaccines, named VacZP2 (Figure 4D) and VacZP3 (Figure 5B), 
which hold the coding region for a truncated porcine ZP protein 2 (∆pZP2, Ile36 – Ala168, 
P42099, uniprot.org) and full-length, porcine ZP3 (Gln23 – Ser332; uniprot.org P42098) as 
antigens. Different studies with porcine ZP2 (Miller and Killian 2002; Hasegawa et al. 2002; 
Hasegawa et al. 2000; Shigeta et al. 2000; Hasegawa et al. 1995; Koyama et al. 1991) and 
other animal’s ZP2 like mouse (Lea et al. 2002; East and Dean 1984), bonnet monkey 
(Govind et al. 2002), brushtail possum (Duckworth et al. 2007), rabbit (Mackenzie et al. 
2006) and human (Chakravarty et al. 2005; Tsubamoto et al. 1999) have shown that this 
component of the ZP is a potential target to decrease mammalian fertility. At the N-
terminus of the homologous murine ZP2 the taxon-specific sperm recognition is located 
(Avella et al. 2014). This was also confirmed by incubation of humane oocytes with 
anti-porcine ∆ZP2 (amino acid 1 - 198), which did not affect sperm binding (Hasegawa et 
al. 2000). ZP3 plays also a crucial role in sperm binding (Chiu et al. 2014; Chen et al. 1998; 
Kinloch et al. 1995) and matrix structure (Liu et al. 1996; Rankin et al. 1996).  
Immunocontraception studies on Kangaroo (Kitchener et al. 2009a), bonnet monkey 
(Afzalpurkar et al. 1995; Bagavant et al. 1994), squirrel monkey (Sacco 1987), marmoset 
(Paterson et al. 1992), dog (Shrestha et al. 2015; Srivastava 2002) and mouse (Hardy et al. 
2003; Millar et al. 1989) with ZP3 as target antigen show high spaying potential. 
Recombinant porcine ZP3 sterilized mice (Gupta et al. 2013; Clydesdale et al. 2004), but 
failed to operate in horses (Joone et al. 2017). Dr. Kirkpatrick (History of PZP, unpublished) 
does not recommend an extrapolation of immunogenicity of a new ZP vaccine from other 
studies, because of a variety of factors influencing an effective immunocontraception. 
Factors are glycosylation and conformation determined by the production source of the 
antigen (e.g. native, recombinant), an allo- or heteroimmuniziation, immunization 
schedule and immunomodulating techniques (e.g. adjuvant, formulation) (Curtis et al. 
2007; Hardy et al. 2003; Dunbar et al. 1994; Dunbar and Raynor 1980). So, every new ZP 
vaccine has to be individually evaluated, but our chosen porcine ∆pZP2 and ZP3 are 
undoubtedly important for fertilization. 
To circumvent MHC restriction, thereby increase the number of individual responders and 
modulate the immune response (cellular vs. humoral), a sophisticated antigen design is 
necessary (Bagavant 1997). Amoung other things, this could be done by creating 
multiepitope antigens (Hardy et al. 2008; Hardy et al. 2004) or promiscuous T-cell epitopes 
coupled to the ZP epitope, like e.g. bovine RNase (Lou et al. 1995a; Chen et al. 1991), KLH 
(Millar et al. 1989) or diphtheria toxin (Srivastava 2002; Govind and Gupta 2000). 
N-terminally fused in frame to the antigens is the non-toxic subunit of cholera toxin (CTB) 
(P01556, uniprot.org) as a humoral adjuvant (Holmgren et al. 2005) enabling a mucosal 
delivery (reviewed in Baldauf et al. 2015) and C-terminally 45 bp of the tetanus toxoid (TT) 
(Gln830 – Leu844, P04958, uniprot.org) as an adjuvant for an effective helper T-cell 
activation (Fraser et al. 2014). The translation is ER-targeted and the protein retains in the 
ER via the retention signal SEKDEL (Denecke et al. 1992). This is necessary for CTB 
pentamer assembling (Mikschofsky et al. 2009a) and ER-targeting is still favorable, 
because this compartment is able to accumulate high amounts of recombinant protein 
(Wandelt et al. 1992) and resident chaperones together with lower proteolytic activity 
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stabilizes proteins and antibodies (Benchabane et al. 2008), like in many studies (Nausch 
et al. 2012b; Mikschofsky et al. 2009a; Stöger et al. 2002; Conrad and Fiedler 1998; 
Schouten et al. 1996). To increase translational efficacy and protein stability additional 
sequence for Ala-Ser-Ser (Sawant et al. 2001) was integrated directly after start codon 
during gene design. To alleviate steric hindrance during auto-assembly of the CTB 
domains a glycine-proline-glycine-proline (GPGP) linker (Ljpscombe et al. 1991) was 
introduced between CTB and pZP2 and ZP3, respectively. The omission of the GPGP linker 
between CTB and a HIV antigen resulted in a reduced ability of the CTB fusion protein to 
form a pentamer (Lee et al. 2014). The di-lysine linker was integrated to probably improve 
antigen processing of the Tetanus Toxoid and thereby stimulate the cellular immune 
response (Sarobe et al. 1993; Takahashi et al. 1988). With the protease site AcTEV (Nayak 
et al. 2003) a separation of TT is possible to allow an influence on the adaptive immune 
response.  
The histidine tag enables an easy purification via affinity chromatography. The protease 
site Factor Xa (Jesty and Nemerson 1976) opens the opportunity to deposit the histidine 
tag. Both fusion gene sequences were optimized by Eurofins GENEius software to plant 
codon usage and to prevent bad motifs, like artificial splicing sites or premature 
polyadenylation signals. The subsequent in silico testing with the prediction server 
NetGene2 (Hebsgaard et al. 1996), showed no putative splice products during plant 
expression. 
To obtain a constitutive expression of VacZP2 in all transformed plant cells the fusion gene 
was integrated into pSingle35S vector, designated as p35S-VacZP2 (Figure 4A). For 
seed-specific expression of VacZP2 and VacZP3-P we used a pLH9000 derivate with a seed 
specific arcelin5-I promoter pARC (Jaeger et al. 2002) cloned by Antje Höhne (unpublished 
data), named pARC-VacZP2 (Figure 4B) and pARC-VacZP3-P (Figure 5A). Transient 
expression of VacZP2 (Figure 4C) and VacZP3-P (Figure 5C) was realized by the cr-TMV / 
TVCV-based MagnICON™ vector pICH29912 provided by Nomad Bioscience (Halle/Saale, 
Germany).  
For determination of antibodies after vaccination with VacZP2, which are exclusively 
directed to the antigen domain ∆pZP2, the domain ∆pZP2 was transiently expressed in 
N. benthamiana via pICH31120 vector (Figure 4F). The resulting protein ∆pZP2onlyP (Figure 
4E) was coated to ELISA plates. The pICH31120 vector is equal to pICH29912, but has an 
integrated ER-targeting sequence from the apple pectinase, a histidine tag and SEKDEL 
sequence.  
VacZP3-B (Figure 5B), the bacterial expressed VacZP3-P, was designed to act as a positive 
control in bioanalytical assays, e.g. Western blot. In order to get a bacterial fusion protein   
similar to the plantal one, ER-targeting sequence of vacZP3-P was deleted and cloned into 
pET22b (Novagen) (Figure 5D). 
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Figure 4: Vectors for VacZP2 expression. (A) p35S-VacZP2 for constitutive expression. 35S: 35S 
transcript of Cauliflower Mosaic Virus; P: promoter; T: terminator. (B) 
pARC-VacZP2 for seed specific expression. arc5-I-P: arcelin5-I promoter of 
Phaseolus vulgaris. (C) pICH-VacZP2 for transient expression. Act2: Arabidopsis 
actin 2; RdRP: RNA dependent RNA polymerase; MP: movement protein of turnip 
vein clearing virus (TVCV); nos: nopaline synthase. (D) Coding region of the fusion 
gene vacZP2. Underlined sequence: addition of the amino acids Ala-Ser-Ser; ER: 
CTB targeting sequence for ER secretion; CTB: cholera toxin subunit B from Vibrio 
cholera; GPGP: Glycine-Proline-Glycine-Proline hinge; ∆pZP2: N-terminal porcine 
Zona pellucida 2 coding region (36 – 168 aa); AcTEV: recognition site for a TMV 
AcTEV protease; KK: di-lysine linker; TT: tetanus toxoid (830 – 844 aa); Factor Xa: 
recognition site for a bovine protease; His tag: 6 Histidine residues; SEKDEL: ER 
retrieval signal. (E) Coding region for pZP2onlyP. ∆pZP2: N-terminal porcine Zona 
pellucida 2 coding region (36 – 168 aa); His tag: 6 Histidine residues; SEKDEL: ER 
retrieval signal. (F) pICH-pZP2onlyP for transient expression. apo: apoplastidal 
targeting sequence from apple pectinase. 
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Figure 5: Vectors for VacZP3 expression. (A) pARC-VacZP3-P for seed specific expression. arc5-I-
P: arcelin5-I promoter of Phaseolus vulgaris. (B) Fusion gene vacZP3-P for plant 
expression. Underlined sequence:  addition of the amino acids Ala-Ser-Ser; ER: CTB 
intrinsic targeting sequence for ER targeting. CTB: cholera toxin subunit B from 
Vibrio cholera; GPGP: Glycine-Proline-Glycine-Proline hinge; ZP3: porcine Zona 
pellucida 3 coding region (23 – 332 aa); AcTEV: recognition site for a TMV AcTEV 
protease (Nayak et al. 2003); KK: di-lysine Linker; TT: tetanus toxoid fragment (830 
– 844 aa); Factor Xa: recognition site for bovine protease (Jesty and Nemerson 
1976); His tag: 6 Histidine residues; SEKDEL: ER retrieval signal; Act2-P: Arabidopsis 
actin 2 promoter; RdRP: RNA dependent RNA polymerase; MP: movement protein 
of turnip vein clearing virus (TVCV) ; NTR: untranslated region of TMV; nos: 
nopaline synthase; RB: right border; LB: left border; 35S: 35S transcript of 
Cauliflower Mosaic Virus, arc5-I: arcelin5-I gene from Phaseolus vulgaris; T7: T-
phage lac operon, P: promoter T: terminator.  
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4.2 Vector construction  
VacZP2 
Constitutive expression of VacZP2 in carrot cells and N. tabacum plants was realized by 
transformation of p35S-VacZP2 (Figure 4A). The coding region was integrated into 
pSingle35S via XmaI and SalI restriction sites and transformed to E. coli TG1. 
Streptomycin20/Spectinomycin50 (St20/Sp50) selected clones were verified by 
colony-PCR with primer pZP2_TT_fw + pZP2_TT_rev (Figure 7A). Clone 4 was used for 
further work. The plasmid was check by NdeI restriction to 531, 1760, 2117 and 6473 bp 
fragments. All fragments were detected (Figure 7B). 
 
Figure 6: Overview of cloning strategies. (A) Constitutive expression of VacZP2. (B) Seed-specific 
expression of VacZP2. (C) Transient expression of VacZP2. p35S…cauliflower 
mosaic virus (CMV) promoter 35S; t35S…CMV terminator 35S; arc5-I…arcelin 5-I 
promoter; ParA, ParB, resolvase…repressor for transposon activity; 
Sm/Sp…streptomycin/spectinomycin resistance gene; km… neomycin 
phosphotransferase II (NPT II) for kanamycin resistance; bla…beta-lactamase gene 
for ampicillin resistance. 
Plasmid from clone 4 was sequenced and transformed to A. tumefaciens strain LB4404. 
All clones growing on St100/Sp300 were PCR positive in a colony-PCR (Figure 7C). To 
ensure that tested agrobacteria were not contaminated with E. coli TG1 carrying 
p35S-VacZP2, a randomly amplified polymorphic (RADP)-PCR was conducted. No 
contamination of E. coli was detected in agrobacteria transformed with this vector and 
the empty vector control, respectively (Figure 8). 
 
Figure 7: Verification of transforming E. coli with p35S-VacZP2. (A) Colony-PCR of p35S-VacZP2 
transformed E. coli TG1 clones with primer pZP2_TT_fw + pZP2_TT_rev. Expected 
band is at 400 bp. 1-14…Clone 1-14. M…Marker DNA Ruler Ladder Mix. (B) 
Restriction of p35S-VacZP2 from clone 4 with NdeI. (C) Colony-PCR of p35S-VacZP2 
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transformed A. tumefaciens LB4404 with same primer like A. Blue arrows show 
expected product. 
 
Figure 8: RAPD-PCR with daf9 primer on p35S-VacZP2 and pSingle35S transformed 
A. tumefaciens clones. 
Seed-specific expression of VacZP2 was established by transformation of tobacco with 
pARC-VacZP2, a pLH9000 (Hausmann and Töpfer 1999) derivate, carries a seed specific 
arcelin5-I promoter from Phaseolus vulgaris (Jaeger et al. 2002) (accession #AF458478). 
VacZP2 coding sequence was transferred via XmaI and SalI restriction sites from 
pUC57-VacZP2 to pARC and selected on streptomycin/spectinomycin (Figure 6B). Positive 
clones were identified by colony-PCR amplifying the ∆pZP2 antigen with pZP2_TT_fw + 
pZP2_TT_rev primer pair (Figure 9A). Integration was also verified by NdeI restriction, 
where all expected fragments were detected (Figure 9B). Positive plasmid was sequenced 
and transformed to A. tumefaciens strain LBA 4404 for stable tobacco transformation. 
 
Figure 9: Verification of transforming E. coli with pARC-VacZP2. (A) Colony-PCR of two 
pARC-VacZP2 transformed E. coli TG1 clones with primer pZP2_TT_fw + 
pZP2_TT_rev. Expected band is at 400 bp. (B) 1...uncut pARC-VacZP2 plasmid DNA, 
2…Restriktion of pARC-VacZP2 with NdeI. All expected bands of 7670, 2128, 1759 
and 531 bp are detected. 
Transient expression in N. benthamiana was realized with the transformation of 
pICH-VacZP2 (Figure 4C). VacZP2 was transferred from pUC57-VacZP2 to pICH29912 by 
BsaI restriction earlier described by Engler et al. 2008. The ligation product was 
transformed to E. coli TG1 and selected on kanamycin. The positive colonies were 
identified by colony-PCR (Table 7) on the integration of vacZP2 between the TMV 
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promoter and terminator with TMV_primer_fw + TMV_primer_rev (1571 bp) and the 
pZP2 antigen by pZP2_TT_fw + pZP2_TT_rev (400 bp) ( 
Figure 10A). Plasmids of clone 2, 4, 5 and 6 were digested with EcoRI to double check the 
integration of vacZP2. A 689 bp fragment validates the plasmids from all tested clones 
(Figure 11). pICH-VacZP2 from clone 6 were transformed into A.t. ICF320 and selected on 
kanamycin and rifampicilin. Positive A.t. clones were identified like positive E. coli clones. 
A.t. clone 1 was chosen for plant transformation (Figure 10B). 
 
Figure 10: Colony-PCR of pICH-VacZP2 transformed (A) E. coli TG1 clones and (B) A. tumefaciens 
ICF320. Primer used: Upper panel…TMV_primer_fw + TMV_primer_rev; lower 
panel…pZP2_TT_fw + pZP2_TT_rev. 
 
 
Figure 11: Restriction of pICH-VacZP2 from E. coli with EcoRI of clone 2-6 (lane 1-4). 
5,6…pICH29912; 7…pICH-VacZP2 clone 2 
ZP2onlyP 
To obtain ∆pZP2onlyP PCR was conducted with primer pZP2_pICH31120f and 
pZP2_pICH31120r with pICH-VacZP2 as template (Figure 13A). PCR product was cloned 
blunt end into pJET1.2 (Thermo Fischer™) and transformed into E. coli TG1 (Figure 12).  
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Figure 12: Overview of cloning steps to pICH-∆ZP2onlyP. bla…beta-lactamase gene for ampicillin 
resistance; km…NPTII gene for kanamycin resistance. 
After selection on ampicillin positive clones were identified by colony-PCR (Table 7) with 
pJET1.2_fw and pJET1.2_rev primer (Figure 13B). The pJET1.2 + ∆pZP2onlyP plasmid from 
clone 4 was positively verified in a sequence alignment (data not shown). ∆pZP2onlyP was 
cloned into pICH31120 via BsaI restriction sites (Engler et al. 2008). Nine clones selected 
on kanamycin were tested in a colony-PCR (Table 7). All clones were positive and the 
pICH-∆pZP2onlyP plasmid from clone 6 was used for transformation of A.t. ICF320 (Figure 
13C). 
 
Figure 13: Verification of transforming E. coli with pICH-VacZP2. (A) Control PCR of pICH-VacZP2 
with primer pZP2_pICH31120f + pZP2_pICH31120r leading to ∆pZP2onlyP (421 bp). 
(B) Colony-PCR of E. coli TG1 transformed with pJET + ∆pZP2onlyP. 1-4…clone 1-4. (C) 
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Colony-PCR of E. coli TG1 transformed with pICH-∆pZP2onlyP. 1-9…clone 1-9. H2O…as 
template. M…DNA Ladder marker. 
VacZP3-P 
The fusion gene was synthesized by Eurofins (Ebersberg, Germany) and delivered in the 
plasmid pUC57 + VacZP3BsaI. To obtain a functional BsaI restriction site vacZP3-P was 
amplified with BsaI_repair_fw and BsaI_repair_rev (Table 9). The PCR product was 
detected in an agarose gel (Figure 15A) cloned blunt end into pJET1.2 plasmid, which 
resulted in pJET1.2 + VacZP3-P (Figure 14). This vector was transformed into E. coli TG1 
and positive clones were identified by colony PCR (Figure 15B) with primer pJET1.2_fw 
and pJET1.2_rev (Table 9). 
 
Figure 14: Cloning vacZP3-P into pJET1.2 gaining a functional BsaI restriction site.  
 
 
 
Figure 15: Verification of transforming E. coli with pUC57 + VacZP3BsaI and pJET + VacZP3-P. (A) 
PCR of pUC57 + VacZP3BsaI with primer BsaI_repair_fw + BsaI_repair_rev (5 µM). 
1…1 µl PCR product. 2…9 µl PCR product. 3…H2O negative control. (B) Colony-PCR 
with primer pJET1.2_fw and pJET1.2_rev on E. coli TG1 transformed with pJET + 
VacZP3-P. 1-11…clone 1 –11. Expected PCR Product: 1614 bp 
Integrity of the plasmid pJET1.2 + VacZP3-P was verified by restriction with PstI and XmaI 
to 4106 and 363 bp (Figure 16). PCR-mediated 3’ BsaI site Integration (Figure 14) was 
tested by HindIII restriction to 271, 396 and 3802 bp fragments. 
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Figure 16: Restriction of pJET1.2 + VacZP3-P clone 2 and 6. 1,2…uncut plasmid; 3…uncut pUC57 + 
VacZP3BsaI; 4,5…plasmid clone 2 and 6 cut with PstI and XmaI; 6,7…plasmid clone 2 
and 6 cut with HindIII; 8…pUC57 + VacZP3BsaI cut with HindIII 
The fusion gene (Figure 5B) was inserted into the binary transformation vector pARC 
(Figure 5A) by XmaI and SmaI restriction sites from pJET1.2 + VacZP3-P and selected by 
streptomycin/spectinomycin (Figure 18A). Clones were tested by colony-PCR for ZP3 
antigen (749 bp) and vacZP3-P (1489 bp) coding region with primer pZP3_Tabak_fw + 
pZP3_Tabak_rev and BsaI_repair_fw + BsaI_repair_rev, respectively (Table 9). All tested 
clones were positive (Figure 17) for both tests.  
 
Figure 17: Colony-PCR of pARC- VacZP3-P transformed E. coli TG1. (A) Test on ZP3 antigen coding 
sequence with pZP3_Tabak_fw + pZP3_Tabak_rev. (B) BsaI_repair_fw + 
BsaI_respair_rev. Spur 1-5…Klon 1-5; Spur 6…positiv Kontrolle; 7…H2O. 
For transient expression we cloned the fusion gene vacZP3-P in the vector pICH29912 
(Figure 5C) by BsaI sites (Engler et al. 2008; Figure 18B). 
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Figure 18: Overview of cloning strategies for VacZP3-P. (A) Seed-specific expression of VacZP3-P. 
arc5-I…arcelin 5-I promotor. ParA, ParB, resolvase…repressor for transposon 
activity; Sm/Sp…streptomycin/spectinomycin resistance gene. (B) Transient 
expression of VacZP3-P. km… neomycin phosphotransferase II (NPT II) for 
kanamycin resistance. bla…beta-lactamase gene for ampicillin resistance 
Plasmid was transformed to E. coli TG1. Positive clones were identified by colony-PCR with 
primer Seq_plCH29912_fw and Seq_plCH29912_rev (Table 9). Plasmid from positive 
clone 10 (Figure 19A) carrying vacZP3-P was purified, sequenced and transformed to 
A. tumefaciens ICF320 strain. Kanamycin-selected clones were verified via colony-PCR, 
wheather they integrated vacZP3-P (1539 bp) with the ZP3 antigen (749 bp) (Figure 19B). 
 
Figure 19: Colony-PCR for pICH-VacZP3-P transformed (A) E. coli TG1. 1-6…Clone 9-14, 7…positive 
control. Expected band: 1559 bp. (B) A. tumefaciens ICF320 clone 2 tested with i) 
lane 1-4…pZP3_Tabak_fw + pZP3_Tabak_rev and ii) lane 5-8… Seq_pICH29912_fw 
+ Seq_pICH29912_rev. 1+5…H2O negative control; 2+6…plasmid DNA diluted 
1:100; 3+7…plasmid DNA diluted 1:20; 4+8…pICH-VacZP3-P plasmid DNA (lane 8 
missing signal) 
VacZP3-B 
To obtain overexpression of VacZP3 in E. coli ER-targeting sequence has to be deleted out 
of the gene and cloned into an IPTG-induceable pET22b (Novagen) expression vector 
(Figure 20). 
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Figure 20: Overview of cloning steps to pET22b + VacZP3-B. bla…beta-lactamase gene for 
ampicillin resistance; km…NPTII gene for kanamycin resistance; lacl…lactose-inducible lac 
operon transcriptional repressor; cphB…cyanophycinase B gene. 
Via PCR program 2 (Table 6) with the primer pair ÜEx_synZP3_XhoI and ÜEx_synZP3_NdeI 
(Table 9) vacZP3-B was created. The PCR product was ligated to vector pJET1.2 with 
CloneJET kit (Thermo Fischer™) and transformed to E. coli TG1. Positiv clones were 
identified by colony-PCR (Figure 21) with the primer pair pJET1.2_fw and pJET1.2_rev 
(Table 9). Clone 5 was pickt for further work. 
 
Figure 21: Colony-PCR with primers pJET1.2_fw + pJET1.2_rev of E. coli TG1 transformed with 
pJET1.2 + VacZP3-B. 1-6…Clone 1–6; 7…Positivkontrolle pJET1.2 + VacZP3-P, 8…H2O 
negative control. 
Because of the same antibiotica resistence of pJET1.2 and pET22b, an intermediate 
cloning step to pET28a via XhoI and NdeI restriction sites was necessary. False positive 
ligation products were linearized by EcoRI restriction. Positive clones growing on 
kanamycin were picked for further work. VacZP3-B was integrated to pET22b via XhoI and 
NdeI and false positive plasmids were linearized by NcoI. pET22b + VacZP3-B carrying E. 
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coli TG1 clones were selected on ampicillin and identified by colony-PCR with primer pair 
pET28a_fw and pET28a_rev (Table 9). Clone 8 was picked and the plasmid was, verified 
by FspI and BspHI restriction and subsequently sequenced. The plasmid was transformed 
to E. coli BL21 for overexpression. 
 
Figure 22: Colony-PCR of E. coli TG1 transformed with pET22b + VacZP3-B. (A) Primer pET28a_fw 
+ pET28a_rev; PCR program 3. (B) Primer pZP3_Tabak_fw + pZP3_Tabak_rev; PCR 
program 4. 1-10…clone 1 – 10; 11…positive control pET28a + VacZP3-B. 12…H2O 
negative control. 
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4.3 VacZP2  
4.3.1 Stable expression of VacZP2 
In order to identify the optimal production system for stable expression of VacZP2 we 
tested carrot cells and tobacco leaves and seeds as models.  
Constitutive expression of VacZP2 in carrot calli 
Carrot suspension cells were transformed using p35SS-VacZP2 (Figure 4A). 28 
independent transgenic calli were identified via PCR (Table 3). Only 11 events show 
significant amounts of CTB with an average expression of 7 ngCTB mg-1TSP. The maximum 
CTB content in calli was 20.7 ngCTB mg-1TSP corresponding to 0.53 ngCTB mg-1DW ( 
Figure 24A).  
Table 3: Overview of expression levels in tobacco leaves, seeds and carrot cells. Level of 
expression was determined by anti-CTB ELISA. n. d. … not determined 
 
Constitutive expression of VacZP2 in in tobacco 
Stable leaf-disc transformation with p35S-VacZP2 showed no reduction in transformation 
rate in comparison to the empty vector (Table 3). After kanamycin selection, 12 PCR 
positive transformants were identified. The highest VacZP2 expression level in leaves was 
0.94 ngCTB mg-1TSP and 0.033 ngCTB mg-1DW, respectively ( 
Figure 24A). The mean accumulation level is 0.38 ngCTB mg-1TSP.  
Seed specific expression of VacZP2 in tobacco 
The arcelin5-I promotor from Phaseolus vulgaris (Goossens et al. 1994) was used to 
induce seed specific VacZP2 expression. N. tabacum Petite Havana SR1 was transformed 
with pARC-VacZP2 (Figure 4B). Out of 79 regenerated plants 24 putative VacZP2 producing 
events were obtained with unaltered development and development compared to the 
empty vector control pSingle35S (Table 3). The top event 59 reached accumulation levels 
up to 2479 ngCTB mg-1TSP in ripe T0 seeds corresponding to 0.24 µgCTB mg-1DW ( 
Figure 24). Nine events produced more than 50% of the CTB identified in 59, but most of 
the events were under 1 µgCTB mg-1TSP and 70 ngCTB mg-1DW, respectively ( 
Figure 24B). Even at room temperature the amount of VacZP2 was stable in seeds for at 
least 18 weeks ( 
Figure 25B).  
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4.3.2 Transient expression of VacZP2 in N. benthamiana 
For transient expression Nicotiana benthamiana plants were vacuum infiltrated with 
Agrobacterium tumefaciens carrying pICH-VacZP2 (Figure 4C). After 7 dpi leaves showed 
dry areas and bleached. This phenotype increased rapidly, but more frequently in plants 
infiltrated with the empty vector (Figure 23).  
 
Figure 23: Leaves of N. benthamiana infiltrated with A. tumefaciens ICF320 carrying 
(A) pICH-VacZP2 and (B) empty pICH29912 vector, (1) 4 dpi (2) 7 dpi and (3) 12 dpi. 
The content of VacZP2 in the freeze-dried leaf material was analyzed via anti-CTB ELISA. 
A significant increase of CTB was observed at the 9th dpi ( 
Figure 26). High variation was detected between the three independent experiments. 
Though no significant accumulation peak could be determined, all plant material for 
VacZP2 production was harvested at day 9. The average VacZP2 accumulation was 4 % 
per TSP (Table 3), which equals 1 µg VacZP2 per mgDW in N. benthamiana. The second 
repetition of the experiment featured the highest accumulation of CTB with 52 µgCTB mg-
1
TSP and 1.2 µgCTB mg-1DW in a pool sample from the leaves of 30 plants ( 
Figure 24A). Tobacco leaves infiltrated with pICH-VacZP2 were freeze-dried and stored at 
room temperature in the dark. Storage for 35 weeks of storage did not significantly reduce 
the CTB content ( 
Figure 25A). After 74 weeks a significant decrease was detected. 
  
Figure 24: CTB concentration in different expression systems in relation to total soluble protein 
(TSP; dark green) and dry weight (DW; light green), respectively. (A) Top producing 
events of carrot cell suspension, constitutive 35S, seed-specific and transient 
expression system, respectively. Error bars show standard deviation. Bar for 
transient expression show a pool of 30 plants. (B) pARC-VacZP2 transformed T0 
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tobacco seeds displayed in a boxplot (only CTB producing events integrated, 
n = 24). 
 
 
Figure 25: Stability of VacZP2 during storage in plant tissue. (A) Content of VacZP2 in transiently 
transformed, freeze-dried tobacco leaves in relation to 0 weeks of storage (red 
bars). (B) Content of VacZP2 in tobacco seeds in relation to 0 weeks of storage (blue 
bars). Error bars show standard deviation. Asterisk indicates a significant difference 
(p < 0.05). 
 
 
Figure 26: Accumulation of VacZP2 in N. benthamiana plants after agrobacterium-mediated 
transformation of pICH-VacZP2 (n = 3). All measurements by anti-CTB 
sandwich ELISA and corrected with values of NIC. Asterisk shows a significant 
difference (p < 0.05). Dark green columns refer to left axis. Light green columns 
refer to right axis. 
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4.3.3 Glycosylation and Stability of VacZP2  
 
Figure 27: Detection of glycosylated VacZP2. (A) Anti-CTB Western Blot. (B) Anti-histidine6 
Western Blot. (C) Concanavalin A Western Blot. Samples are elution fractions after 
Ni-NTA purification. …potential monomer of VacZP2. …potential dimers of 
VacZP2. …potential multimers2<n≥5 VacZP2. (D) Schematic representation of 
VacZP2. Stars show potential N-glycosylation sites. (E) Northern blot analysis of 2 
µg RNA, isolated from N. benthamiana leaves, using a CTB probe. Lane 1: RNA from 
empty MagnICON™ vector in N. benthamiana. Lane 2: RNA from N. benthamiana 
leaves transformed with pICH-VacZP2 (expected mRNA: 1178 bp). 
Based on the high expression level of VacZP2, the MagnICON system was chosen as 
production platform. To test the quality of VacZP2 after harvest the purified VacZP2 was 
separated via 12 % SDS-PAGE and an anti-CTB, anti-histidine or Concanavalin A Western 
blot analysis was performed (Figure 27ABC). Two proteins of around 35 and 41 kDa were 
detected in the elution fractions of Ni-NTA column in all three blots (one triangle). These 
proteins are slightly bigger than the calculated 32.2 kDa for the monomeric, non-
glycosylated VacZP2 using the ProtParam tool (expasy.com). Presuming 3 kDa per 
N-glycan, protein masses between 35 and 44 kDa were expected for a glycosylated VacZP2 
monomer, corresponding to the number of potential maximal four N-glycosylation sites 
(Figure 27D).  
In addition, various bands between 70 and 250 kDa were detected in all three Western 
blots (Figure 27ABC), which could represent oligomers of VacZP2 oligomerized base on 
the CTB domain.  
Lower bands between 12 and 18 kDa are detectable in anti-CTB and Concanavalin A 
Western blot analysis (Figure 27AC), but not in the anti-histidine Western blot analysis 
(Figure 27B). These signals correspond to monomeric (11.6 kDa), non-, once (15 kDa) and 
twice glycosylated CTB (18 kDa), respectively, if a glycan mass of 3 kDa is assumed (Mishra 
et al. 2006). Bands between 25 and 35 kDa may represent dimers of the CTB molecules.  
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An RNA corresponding to the length of the smallest viral RNA of vacZP2 (1178 nt) was 
detected in Northern blot analysis using CTB as probe (Figure 27E). In addition, a small 
RNA was detected at 483 bp. The analysis of the DNA sequence downstream of the CTB 
coding region did not reveal any specific transcriptional termination signal (Suppl. 1). 
4.3.4 Purification and Quantification of VacZP2 
 
Figure 28: Stability of VacZP2 in tobacco leaf extracts over time. Detection using anti-CTB 
Western blot analysis. (A) 5 µl protein extract incubated at 21 °C. (B) 5 µl protein 
extract incubated at 4 °C. (C) 2.5 µl protein extract incubated at 21 °C with protease 
inhibitor mix. (D) 4.5 µg total protein of elution fraction of VacZP2 in 1x PBS (pH 
7.2) after Ni-NTA purification. …potential monomeric VacZP2. …potential dimer 
of VacZP2.  
Potentially monomeric and dimeric VacZP2 decreases in leaf extract at room temperature 
(Figure 28A). This effect is alleviated when TSP extract is stored at 4 °C (Figure 28B). A 
complete stabilization is achieved by addition of a protease inhibitor mix (Figure 28C) or 
after purification via a Ni-NTA column (Figure 28D). The signal for putative CTB oligomers 
became stronger during incubation (Figure 28A, B, D). Signals between 12 and 18 kDa 
potentially representing CTB are present immediately after TSP extraction independent 
of protease inhibitor addition or cooling.  
Since free CTB molecules are still present in the purified vaccine (Figure 28D), they lead 
to an overestimation of antigen in the anti-CTB ELISA. To estimate the content of VacZP2, 
we calculated the ratio of free CTB molecules in TSP by densitometric analysis of Western 
blot signals via image processing (ImageJ) (Suppl. 5). VacZP2 accounts for 88% of the full 
fusion protein in the vaccine. 
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4.3.5 Transient expression of pZP2onlyP  
The Concanavalin A Western blot analysis of VacZP2 (Figure 27) shows glycosylation of 
the whole fusion protein, nevertheless it is not possible to distinguish between 
glycosylations of pZP2 and the rest of the fusion protein. To be ascertained whether 
pZP2 or CTB is glycosylated, pZP2 alone was integrated into the vector pICH31120 
(ZP2onlyP, Figure 4F) and transiently expressed in N. benthamiana. In the anti-histidine 
Western blot analysis and Coomassie stained SDS-PAGE a signal with the expected size of 
pZP2onlyP between 17 and 20 kDa was identified (Figure 29AB). This signal was also found 
in the lectin blot, which proofs that at least one glycosylation site is recognized in pZP2 
(Figure 29C). The signal in the anti-histidine western blot between 17 and 20 kDa is very 
strong and could be a double signal of non- and once glycosylated monomer. Two signals 
around 35 kDa might be a result of dimerization. A signal at 11 kDa could be a hint for 
proteolytical sensitivity of ZP2onlyP. 
 
Figure 29: Detection of pZP2onlyP after expression via MagnICON. (A) Anti-histidine Western blot 
analysis. (B) Coomassie stained 12 % SDS PAGE. (C) Concanavalin A conjugated POD 
detects high mannose residues. …potential pZP2onlyP. Unglycosylated calculated 
mass is 16.7 kDa. 
70
55
35
15
10
25
130
100
250
A
70
55
35
15
10
25
130
100
250
B
70
55
35
15
10
25
130
100
250
C
46____Results  
 
4.3.6 Animal trial 
Strong immune response in mice 
The immunogenicity of VacZP2 was tested via three parenteral applications of 264 µg 
fusion protein per mouse. Sera of all bleedings were equally diluted 1:50,000 and 
measured in microtiter plates coated with the vaccine (Figure 30A). After subcutaneous 
priming (day 2) no significant immune response was observed in the second bleeding (day 
21), when the sera diluted 1:50,000 measured against the complete VacZP2 vaccine. But 
a lower dilution of 1:100 shows a significant increase after priming with VacZP2, which 
was approx. 7-fold higher with adjuvant (Suppl. 7). After first subcutaneous booster 
injection of 264 µg vaccine (day 26) we observed a significant increase of antibodies in the 
third bleeding (day 37), no matter whether VacZP2 was delivered with or without 
adjuvant. A second booster with 264 µg vaccine raises the immune response significantly. 
 
Figure 30: (A) Detection of antibodies against VacZP2 in FvB/NcrL mice. Sera were diluted 
1:50,000. (B) Detection of antibodies against pZP2onlyP in FvB/NcrL mice. Same 
sera like in A, but diluted 1:5,000. Error bars show standard deviation. Significance 
classes calculated by post-hoc Tukey-HSD (p > 0.05). (C): Timeline of the 
immunization schedule. Bleeding (red drops) and vaccination (blue triangles) 
regime of FvB/NcrL mice during the animal trial. 
To analyze whether the response is only connected to CTB and TT or also to the pZP2 
domain, microtiter plates are coated with pZP2onlyP, a plant-derived pZP2 peptide. The 
sera of all immunized animals were diluted 1:5,000 and measured in this ELISA. After 
priming, antigen specific pZP2 antibodies showed a significant increase, when applied 
with adjuvant (Figure 30B). Second boostering resulted in no further increase of the 
immune response. 
Hamster infertile after VacZP2 vaccination 
Eight animals of golden hamster were immunized three times with 20 µg VacZP2 + 10 % 
Polygen. Antibody titer as well as against the fusion protein VacZP2 and the pZP2 antigen 
domain by coating the plant-made pZP2onlyP petide to the ELISA plate. After priming, a 
significant increase of antibodies against VacZP2 were visible (Figure 31A). Antibody titer 
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significantly increased after first boost against fusion protein and antigen domain. 
Subsequent booster injections did not increase the titer. 
Four of eight animals were mated with males of proven fertility. Two animals had no litter 
(Figure 31B). In the control group, all animals were pregnant. The two spayed females 
from the VacZP2 group were mated again at day 63 and day 59 without additional 
vaccination and each gave birth to 16 pups (data not shown).  
 
Figure 31: (A) Detection of anti-VacZP2 and anti-pZP2onlyP antibodies after vaccination of golden 
hamster with 20 µg VacZP2 + 10 % Polygen. Sera were diluted 1:1,000. Values were 
corrected by PBS group titer. Error bars show standard deviation. (B) Number of 
born pups after three immunizations. (C) Timeline of VacZP2 vaccination (blue 
triangles), bleedings (red drops), mating (yellow star) and ovariectomy (green 
diamond). Asterisk show significant difference (p < 0.05, Tukey-HSD)  
The remaining four animals in each group were subsequently vaccinated with the same 
amounts and euthanized at day 84. Ovaries were surgically removed and histologically 
examined. The histological evaluation of the female reproductive tract (ovary, oviduct and 
uterus) on day 84 after the last protein application revealed no signs of inflammation in 
any animal under investigation. Corpora lutea as well as follicles in different stages of 
development were present on the ovaries of all animals, suggesting normal cyclicity.  
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4.4 VacZP3 
4.4.1 Constitutive Expression of VacZP3-P in seeds 
Tobacco 
The transformation with pARC-VacZP3-P led to similar regeneration rates and phenotype 
of the transformands compared to the empty vector control. 16 events were selected for 
seed production. All events produced normal amounts of viable seeds except event 144 
which produced a mixture of full and empty seeds which contained the highest amount 
of CTB (303 ng/mg TSP). For protein isolation seeds from ten capsules of each event were 
pooled and the CTB content was measured in an anti-CTB ELISA. The average 
accumulation of VacZP3-P in seeds of the top six events was 0.008 % / total soluble protein 
(TSP) and 9 ng/mg dry weight (DW) (Figure 33A). 
In dry seeds the fusion protein was stable for over 84 weeks (Figure 34B). 
Pea 
Transformation of 750 seeds with pARC-VacZP3-P resulted in 30 positively tested 
transgenic plants, 23 of which were cultivated for seed production. No aberrant 
phenotype was observed during in-vitro cultivation. Samples were taken from at least 
four randomly chosen seeds of each event and tested in the anti-CTB ELISA, except event 
17, which only produced one seed. Seeds, where no CTB could be detected, were defined 
as non-producer and sorted out. We received 18 CTB producing events. 13 of all producing 
events exhibited less than 50% of the CTB/TSP accumulated in the top event 16 with 0.53 
ngCTB / mgTSP-1 and 0.01 ngCTB / mgDW-1 on average (Figure 33B). The top producing seed of 
event 16 accumulated 9.3 x 10-5 % CTB /TSP.  
4.4.2 Transient expression of VacZP3-P in N. benthamiana leaves 
 
Figure 32: Phenotypical changes of pICH-VacZP3 infiltrated N. benthamiana leaves after 5 and 10 
days post infiltration (dpi). 
Eleven N. benthamiana plants were vacuum infiltrated with A. tumefaciens ICF320 
carrying plasmid VacZP3-P (Figure 5C) in minimal 3 repetitions.  In order to determine the 
accumulation of VacZP3-P, minimal four single leaves with different developmental stages 
were harvested from 3 till 13 days post-infiltration (dpi) and freeze-dried. The CTB content 
5 dpi
10 dpi
pICH-VacZP3-P pICH29912 uninfiltrated
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in the leaves was analyzed by an anti-CTB sandwich ELISA with commercially available CTB 
as standard. The maximal mean accumulation in leaves of 3.76 µgCTB · mgTSP-1 is reached 
at the 11th dpi, which is significantly different to day three and four (Figure 33C). 
pICH-VacZP3-P infiltrated leaves bleached and dried out. This effect was even stronger in 
leaves infiltrated with the empty vector (Figure 32). Therefore, in the vaccine production 
phase plants were harvested at 11th dpi. 
According to the CTB detected per TSP the transient expression of VacZP3-P was 
approximately 12 times higher compared to tobacco seeds and over 4500 times higher 
compared to pea seeds both under control of the arcelin promoter.  
 
Figure 33: Accumulation of VacZP3-P in different plant expressions systems measured by anti-
CTB ELISA (corrected by empty vector control). Dark green bars refer to left axis 
and light green bars to right axis, respectively. (A) VacZP3-P in pooled T1 tobacco 
seeds. (B) VacZP3-P in producing T1 pea seeds. Non-producers are excluded from 
the calculation. (C) VacZP3-P in tobacco leaves after transient expression. (ndark green 
= 5, nlight green = 3). (D) Highest CTB concentrations of each expression system. 
Transient expression: values of 11th dpi already shown in C; Tobacco seed event 
144; Pea seeds: Mean value of the five highest expressing seeds from event 16. 
Error bars show standard deviation. Numbers on top of each bar show mean value. 
Logarithmic scale. Asterisks show significance (p < 0.05; Tukey-HSD).  
After freeze-drying, the CTB content was not reduced significantly (data not shown). Also, 
storage of freeze-dried tobacco leaf material did not decrease the CTB content for at least 
21 weeks at room temperature in the dark. After 68 weeks of storage a significant 
reduction of about 40 % was observed (Figure 34A).  
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Figure 34: Stability of VacZP3-P during storage in plant tissue. (A) Content of VacZP3-P in 
transiently transformed, freeze-dried tobacco leaves in relation to 0 weeks of 
storage (red bars, n = 7) (B) Content of VacZP3-P in tobacco seeds in relation to 0 
weeks of storage (blue bars, n = 7). Error bars show standard deviation. Asterisk 
indicates a significant difference (p < 0.05). 
4.4.3 Glycosylation and assembly of VacZP3-P  
 
Figure 35: Detection of VacZP3-P via Western Blot with different primary antibodies. (A) Anti-
CTB. (B) Anti-histidine tag. (C) Concanavalin A. Samples of VacZP3-P and VacZP3-B 
are elution fractions after Ni-NTA purification. (D) Schematic figure of VacZP3-P 
monomeric fusion protein. Stars show potential N-glycosylation sites.  
Transiently expressed VacZP3-P was detected in Western blots with antibodies binding 
either to the N- (anti-CTB, Figure 35A) or C- (Anti-histidine, Figure 35B) terminus of the 
fusion protein. E. coli derived VacZP3-B served as positive control. Based on the data 
published for CTB, where N-glycosylation varied between 1.5 (Matoba et al. 2009), 2 
(Hamorsky et al. 2015) and 3 kDa (Mishra et al. 2006), we calculated each putative 
N-glycosylation (Asn-X-Thr/Ser) of the fusion protein with a mass increase of 3 kDa. 
According to this assumption and dependent on the number of glycosylation sites 
occupied the plant made VacZP3-P should have a size between 55 and 73 kDa. Only one 
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band at 69 kDa could be detected in anti-CTB, anti-His and Concanavalin A Western blots. 
This 69 kDa band was not visible, when VacZP3 was bacterially expressed, hence 
homogenous, possibly incomplete glycosylation or lighter N-glycans at the plant-made 
protein can be assumed (Figure 35).  
Signals above 130 kDa detected in anti-CTB and Concanavalin A Western blot analysis 
might refer to glycosylated VacZP3-P dimers with an expected mass between 121 and 145 
kDa (Suppl. 2C, Figure 35A). Due to the fusion to CTB VacZP3-P should assemble to a 
pentamer (Kwon and Daniell 2016; Yasuda et al. 1998). Nevertheless, even with lower 
acrylamide concentrations (6%) and a native protein separation, the precise 
determination of molecular mass of the expected multimers / pentamers were not 
possible (Suppl. 2C).  However, the formation of pentamers could be proven by a GM1 
ELISA of crude protein VacZP3-P extracts ( 
Suppl. 3A) since only the pentamers bind to the mono-sialoganglioside GM1 receptor 
(Wolf et al. 1981; Dakterzada et al. 2012).  
4.4.4 Quantification of VacZP3-P  
The amount of fusion protein was quantified by an anti-CTB ELISA. In order to identify the 
quantity of intact fusion protein in the vaccine, potential degradation of the fusion protein 
was analyzed via Western blot analysis. Degradation products smaller than the VacZP3-P 
monomer was observed via anti-CTB Western blot analysis directly after isolation (Figure 
36A). This phenomenon could not be avoided by the addition of protease inhibitors 
(Figure 36C) or change of the isolation buffer (Davoodi-Semiromi et al. 2010) (Suppl. 4). 
The strongest signals were between 10 and 20 kDa in the anti-CTB Western blot analysis. 
These signals match the size of non-, once and twice glycosylated CTB monomers, when 
a glycan mass of 3 kDa is assumed (Mishra et al. 2006). Northern blot analysis with a CTB 
probe gave a signal for the smallest viral mRNA of vacZP3-P (1709 nt) and a very weak for 
an around 483 nt long mRNA (Figure 36G), which is longer than the coding region for CTB 
from ATG to the GPGP linker (381 bp). Untranlated regions at the 5’ and 3’ end of the 
vacZP3-P gene could cause this size. But no transcriptional stop or poly a signal was 
detected (Suppl. 6) in the sequence at approx. 380 bp, which would explain the 
occurrence of the small CTB.   
A general degradation of VacZP3-B was observed directly after isolation from E. coli under 
denaturating (data not shown) and native conditions in anti-CTB Western blot analysis 
(Figure 35A). The degradation products match most of those detected in the plant taking 
the lack of glycosylation into account, however, a degradation product matching the size 
of CTB could not be detected. The anti-CTB Northern blot analysis with VacZP3-B detected 
no smaller mRNA fitting to CTB monomer molecules (Figure 36G). 
Incubation of VacZP3-P monomers isolated either from plants or bacteria in crude extracts 
of untransformed N. benthamiana at room temperature reproductively (n=3) resulted in 
degradation of the proteins detected via anti-CTB Western blot analysis (Figure 36AE). 
With cooling or addition of protease inhibitor mix the degradation of VacZP3-P could be 
reduced (Figure 36BC) and completely vanished after purification via Ni-NTA column 
(Figure 36D). An increase of degradation products of VacZP3-P during incubation was not 
observed.  
52____Results  
 
 
Figure 36: Stability of VacZP3. (A – D) Anti-CTB Western Blot of VacZP3-P in tobacco leaf extract 
at (A) 21 °C, (B) 4 °C and (C) 21 °C with protease inhibitor mix, respectively. (D) 
Incubation of VacZP3-P in 1x PBS (pH 7.2) after Ni-NTA purification. (E) Anti-CTB 
Western blot analysis with 10 µg of VacZP3-B incubated in 10 µg tobacco crude 
extract at room temperature for maximum 6 hours. (F) Same loading like E, but gel 
stained with Coomassie. (G) Anti-CTB Northern blot analysis of 5 µg RNA from N. 
benthamiana leaves and 2 µg from E. coli transformed with pICH-VacZP3-P and 
pET-VacZP3-B, respectively.  
Since free CTB molecules in the extracts lead to an overestimation of VacZP3-P in the Anti-
CTB ELISA we determined the amount of free CTB via densitometric analysis. According to 
these results the actual VacZP3-P content in the plant is 8% less then estimated via the 
Anti-CTB ELISA (Suppl. 5) 
4.4.5 Plant-made VacZP3-P is more immunogenic than the 
bacterial control 
Three groups of ten mice were vaccinated three times with two, seven and 21 µg 
VacZP3-P, respectively. Animals were retrobulbary bled once before and three times 
several days after each treatment (Figure 37C). A significant increase of the antibody titer 
was observed after priming with two, seven and 21 µg VacZP3-P (Figure 37A). After the 
first boost, all VacZP3-P vaccinated mice more than doubled the amount of antibodies in 
their blood and were significantly different to the PBS control group. Across the 
experiment there is no significant difference in antibody titer between 2 and 7 µg 
VacZP3-P vaccination. After two boosts the group, which received 21 µg VacZP3-P 
exhibited an 18 % higher titer than the two other VacZP3-P groups. The bacterial fusion 
protein TT-KK-ZP3 (Gupta et al. 2013) was used to verify the responsiveness of the BALB/c 
mice to porcine ZP3 antigen. Antibodies against VacZP3-P were not able to bind to 
immobilized TT-KK-ZP3. 
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Figure 37: Antibody titer of vaccinated female BALB/c mice (n = 10 per group, 9 mice at day 72 
receiving 2 and 7 µg VacZP3-P). All doses contained 10 % Polygen as adjuvant. 
Letters show homogenous subsets by Tukey-HSD. (A) All sera were diluted 1:6,000 
and measured against VacZP3-P, coated on microtiter plates. (B) All sera diluted 
1:500 and measured against bacterial TT-KK-pZP3 (Gupta et al. 2013), coated on 
microtiter plates. (C) Regime of vaccination. Blue triangles...time point of 
vaccination; Red drops...time point of bleeding.  
On day 82 mice were mated with fertility proven males. A dosage-dependent litter 
reduction was observed (Table 4). The offspring in group four, which received 21 µg 
VacZP3-P, was reduced 43 % in comparison to the PBS control group, which had regular 
numbers of pups. Nevertheless, the reduction was not significant. Comparing plant and 
bacterial vaccine, VacZP3-P had a stronger, but not significant, influence on fertility. No 
correlation between antibody titer and sterility was observed.  
Table 4: Mating studies with vaccinated BALB/c mice. 
Group 
Failed to 
conceive 
Pups 
1 PBS                           + 10 % Polygen 0 of 10 60 
2 2 µg   VacZP3-P      + 10 % Polygen 0 of 10 53 
3 7 µg   VacZP3-P      + 10 % Polygen 1 of 10 36 
4 21 µg VacZP3-P      + 10 % Polygen 3 of 9 26 
5 25 µg TT-KK-pZP3  + 10 % Polygen 1 of 10 42 
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5. Discussion 
VacZP2 and VacZP3-P were detected in all plant expression systems. Tobacco seeds and 
transient expression exhibited high, table transformed carrot cells, tobacco leaves and 
pea seeds exhibited low accumulation levels. Promoter, stability, intracellular targeting 
and the host define the expression and accumulation level of the plant made 
pharmaceutical (Schillberg et al. 2005; Faye et al. 2005a; Stöger et al. 2002), which was 
the reason to test a variety of plant production platforms for expressing VacZP2 and 
VacZP3-P. To pick one of the listed, the stability, it includes the stability of the transcript 
at RNA level leading to an efficient translation to the protein and the resistance against 
endogenous proteases at protein level (Stöger et al. 2002). On the one hand it is defined 
in the nucleotide and amino acid sequence of the transgene, in the other hand at the plant 
host itself, owing specific transcription/translation features and specific proteases, which 
distinguish it to other plant species. The expression of scFv84.66 in different plant species 
under the control of the 35SS promotor exhibited a the variation in in tobacco, rice and 
tomato leaves (Stöger et al. 2002), documenting host-dependend accumulation level. 
Even the relatively minor difference of the genetic background in cultivars of one species 
could lead to different accumulation levels of a recombinant protein (Nausch et al. 2012a).  
It was necessary to experimentally test different plant expression systems to evaluate the 
optimal expression system in this study. 
5.1 Expression systems 
Carrot cells  
VacZP2 transformed carrot cells (cv. Rotin) expressed up to to 0.53 µgCTB/gDW under the 
control of the CaMV35S promoter. This result is very poor for carrot cell expression, but 
not alone with low yield in this setting (Mikschofsky et al. 2009c). Carrot is widely used in 
biotechnology and is capable of establishing high production. In 2012, it became the 
production platform of the first approved plant-made enzyme for human therapy against 
Gaucher disease (Protalix.com). Protalix uses a different setting for production. It 
cultivates the transgenic carrot cells in liquid suspension media, stores their 
glucocerebrosidase inside of vacuoles, and uses a different terminator (octopine 
synthase) and another translational enhancer element (Ω translational element). All these 
factors are different to our setting and could influence the outcome. Promoter, transgene 
and terminator have to be appropriate to each other and determine the expression level 
(Nagaya et al. 2010). Changing our settings of expression vector to this of Protalix could 
result in a higher accumulation level. Furthermore, the enhancer element could improve 
translational efficacy and resulting yield (Chen et al. 2001). 
It could also be possible that the activity of metabolism is lower in calli on solid agarose 
than in liquid suspension media, because nutrient supply should be much better in liquid 
media (Ziv 1995). In consequence the synthesis of VacZP2 may be higher in carrot 
suspension culture. In regard to the storage compartment, a change of localizing VacZP2 
to the vacuole might increase the yield. Protein sequestration in subcellular 
compartments is known to be a major factor to stabilize recombinant proteins in plants 
(Benchabane et al. 2008). Vacuoles host different specific enzymatic conditions, including 
protease composition and pH. E.g. complement factor 5a (C5a) accumulated better in 
vacuole of tobacco cells than in ER or apoplast (Nausch et al. 2012b). It could be a measure 
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to increase accumulation of VacZP2 in carrot cells, because of detected protease 
sensitivity of tobacco-derived VacZP2. It could also be an improvement strategy to use 
another cultivar of carrot than Rotin. Mikschofsky et al. 2009c has shown that an 
expression of VP60 in the cultivar Gelbe Futter exhibit a more than 2.5-fold increase in 
comparison to Rotin. Kalbina et al. 2011 used the carrot cultivar Karotan and Napoli and 
produced a Chlamydia trachomatis vaccine with up to 3 % of, which is 1449-times higher 
in comparison to our VacZP2 accumulation.   
Tobacco leaf 
VacZP2 was accumulated up to 0.000094 % of TSP in the top event. This detected amount 
is very low but showed in two independent measurements a clear distinction to the empty 
vector control. Due to the CaMV35S, known as a strong constitutive promoter (Stöger et 
al. 2005), this low outcome is unexpected. The promoter is able to express a scFv antibody 
in tobacco leaves up to 6.8 % of TSP (Fiedler et al. 1997).  
Although no matches were found in MEROPS database, specific sequences at protein level 
of VacZP2 could be consensus sequences for proteases. Proteolytic degradation of 
heterologous proteins is the major factor for low accumulation (Desai et al. 2010). A 
stabilization of the VacZP2 by fusion or co-expression of stabilizing partners/agents or 
gene sequence optimization to avoid protease consensus sequences are two measures 
(Desai et al. 2010; Benchabane et al. 2008). Also, a change of the subcellular localization, 
already suggested for VacZP2 expression in carrot calli, could be an approach to increase 
vaccine accumulation. A good example for this is the expression of the human epidermal 
growth factor (hEGF) via CaMV35S in tobacco leaves. Though, mRNA transcript level was 
high, the expression in the cytosol was with 0.001 % of TSP low (Higo et al. 1993). A 
localization to the apoplast increases the accumulation to up to 0.11 % of TSP (Wirth et 
al. 2004). Expression platform and expression vector have to be appropriate to each other 
(Gecchele et al. 2015) and our p35S-VacZP2 seems not to fit to tobacco leaf expression 
under these conditions. 
Due to the low number of 12 gained positively transformed events, it is not excluded, that 
none of these events exhibits a good insertion locus. Mikschofsky et al. 2009b gained only 
one line exhibiting the heterologous protein CTB::VP60, although 19 DNA-positive 
transgenic tobacco events were created. It is always better to generate a great number of 
transgenic events to get a high expressing events (Boothe et al. 2010). 
Tobacco seeds 
VacZP2 and VacZP3-P were accumulated up to 0.25 and 0.03 % of TSP, respectively. In 
comparison to other seed-specific expressed biopharmaceuticals the accumulation level 
is quiet low (Boothe et al. 2010). We used the highly potent arcelin5-I promoter for 
seed-specific expression. It was derived from the garden bean (Romero Andreas et al. 
1986) and controls the expression of arcelin, a lectin serving for herbivore resistance  in 
the cotyledons (Goossens et al. 1994). Jaeger et al. 2002 showed with this promoter a 
more than 100-fold higher yield of a scFv nanobody per gramm (36.6 % of TSP) in 
Arabidopsis. Host, transgene and terminator are different to our setting and have major 
influence of the outcome. However, which of these factors should be adjusted to increase 
the accumulation level of VacZP2 and VacZP3-P is not clear so far. 
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Tobacco seeds as host is potent for expressing high levels of heterologous proteins (Floss 
et al. 2009, 2009; Tiwari et al. 2009; Scheller et al. 2006; Petruccelli et al. 2006; Ramírez 
et al. 2001; Tackaberry et al. 1999). Besides Arabidopsis (Jaeger et al. 2002; Goossens 
1999), Tepary bean (Goossens 1999) and pea seeds (Dr. Huckauf, personal 
communication), we showed, that the legume arcelin5-I promoter is also transferable to 
tobacco. It is not new to transfer a legume promoter to tobacco. The legume phaseolin 
promoter accumulated high level of up to 1.1 µg monoclonal antibody per mg dry tobacco 
seeds in the first generation (Sengupta-Gopalan et al. 1985). This validates a general 
transfer of legume-specific promoters to tobacco seeds as high potential (Hernández-
Velázquez et al. 2015). But it is possible, that the arcelin5-I promoter performs not so well 
in tobacco than in Arabidopsis, similar to the phaseolin promoter (Hernández-Velázquez 
et al. 2015; Morandini et al. 2011). If a morphological difference between Arabidopsis and 
tobacco seed, e.g. the structure of the endosperm, could affect the capacity to store less 
heterologous protein or transcription and protein synthesis machinery of Arabidopsis is 
more compatible with the regulatory sequences of the vector is not clear (Morandini et 
al. 2011). A change of host for VacZP2 and VacZP3-P expression could be an option to 
improvement promoter activity and RNA/protein stability, respectively. 
The transgenes of VacZP2 and VacZP3-P could also influence the performance of arcelin5-I 
promoter. Boothe et al. 2010 shows in Arabidopsis seeds that accumulation of the bovine 
chymosin is equal under the control of phaseolin and arcelin promoter, but arcelin 
promoter is much less efficient than phaseolin when expressing maize oleosin. In our case, 
sequences and lengths of the constructs seem to be important. The sequence of VacZP2 
is 57 % shorter than VacZP3-P and they differ within the antigen domain. Other domains 
and regulatory sequences are the same. But this difference leads to an 8-fold difference 
in accumulation level (VacZP2 > VacZP3-P). Sequence truncation of the 65 kDa isoform of 
human glutamic acid decarboxylase (hGAD65) resulted in an altering accumulation level 
in tobacco (Merlin et al. 2016). Here a positive correlation between improved solubility 
and protein stability in the transient expression system was assumed. Whether stability 
or expression strength is influenced by the transgenes of VacZP2 and VacZP3-P is not 
clear. 
(Jaeger et al. 2002) used an arcelin terminator. This 5’ regulatory element could be more 
suitable for seed specific expression than the CaMV 35S terminator we used. It is known, 
that expression under the CaMV promoter and terminator is less effective in seeds 
(Nausch et al. 2012a). It is possible, that the 35S terminator lowers the high expression 
rate of the arcelin5-I promoter in the tobacco seeds. A change to the 3’ regulatory 
sequences of the arcelin gene (Goossens et al. 1999) could increase accumulation level of 
VacZP2 and VacZP3-P by providing a more appropriate combination to the promoter 
(Nagaya et al. 2010). 
Since tobacco seeds offer a protective environment for heterologous proteins (Fiedler and 
Conrad 1995), the CTB concentration measured by ELISA did not significantly decrease 
during the experiment of 18 and 84 weeks for VacZP2 and VacZP3-P, respectively. The 
stability of VacZP2 was only tested for 18 weeks. It is probable that it is similarly stable 
like VacZP3-P. Because neither detection of VacZP2 nor VacZP3-P via the anti-CTB 
Western blot analysis was achieved, it is not clear, if the whole CTB-VacZP fusion protein 
was stable. In comparison to the stability of scFV antibodies for 52 and 72 weeks  in 
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transgenic tobacco seeds (Ramírez et al. 2001; Fiedler and Conrad 1995), VacZP2 is equally 
stable. VacZP3-P has to be tested again after 84 weeks of storage to compare it to 
VacZP3-P. 
Pea seeds 
VacZP3-P was also expressed in pea seeds. It was accumulated in pea seeds at top event 
16 up to 0.00008 % of TSP. The accumulation level is very low in comparison to other pea 
seed-specific expression studies. For example, Saalbach et al. 2001 accumulated a scFv 
antibody via USP promoter to up to 2 % of TSP and Zimmermann et al. 2009 obtained 
approximately up to 0.4 % of TSP. In comparison to the expression of the CTB::VP60 fusion 
protein, the VacZP3-P accumulation is nearly 2,500-times lower (Dr. Huckauf, personal 
communication). Thus, they use exactly the same expression vector the only difference is 
the protein itself. So, the construct design and protein determine the stability and in case 
of the ZP vaccines it seems not very stable or no event with a good integration locus was 
obtained. The number of events should be increased.  
Comparison between carrot and tobacco leaf  
In carrot calli the expression under the control of the CaMV35S of VacZP2 was 16-fold 
higher than in tobacco leafs regarding to the dry mass. The reasons for this difference 
could be the plant species. They harbor different kinds of proteases and enzymes due to 
their different physiological setup as totipotent cells and photosynthetic tissue, 
respectively. Artificial cultivation conditions during in-vitro cultivation could cause 
somaclonal variation and stress leading to transgene inactivation (Mikschofsky et al. 
2009c). These stress factors are different from those affecting the vegetative tobacco 
leave tissue (Gaspar et al. 2002). The accumulation level strongly depends on the 
transgene itself and the combination of the regulatory elements 5’ and 3’ (Nagaya et al. 
2010). E.g. the expression of VP60 in other plant species than carrot (0.084 
µgVP60/mgTSP) exhibited an increase in tobacco (0.5 µgVP60/mgTSP) and potato leaves 
(2.5 µgVP60/mgTSP) (Mikschofsky 2006). To take the advantages of suspension culture, 
another cell suspension system like tobacco BY2 or rice or/and the change of the 
promoter might show higher yields.  Shin et al. 2003 has shown that the change of the 
expression system from tobacco cell suspension with a constitutive promoter to rice cell 
suspension with an inducible promoter increased the accumulation of human 
granulocyte-macrophage colony stimulating factor (hGM-CSF).  
Comparison pea and tobacco seeds 
The extreme difference (583-times) of VacZP3-P accumulation in tobacco and pea seeds 
under the control of the arcelin promoter could be reasoned by the host. Both plant 
species own proteases with individual cleavage sites (MEROPS) and it is well-known, that 
host-own factors determine the levels of accumulation in seeds (Hernández et al. 2013). 
E.g. phaseolin undergoes no major proteolytic processing in the garden bean, but 70 % is 
cleaved in transgenic tobacco seeds to smaller peptides (Higgins et al. 1988). This effect 
of species-specific protein processing/stability and reaction to the expression cassette 
could also be the reason why Morandini et al. 2011 detected 16- and 21-times less 
heterologous chimeric GAD67/65 protein driven by an phaseolin promoter in tobacco and 
petunia seeds than in Arabidopsis seeds. These differences in protein processing and 
stability could also be explained by morphological differences. Pea store most of their 
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proteins in the cotyledons (Beevers 1968), whereas tobacco stores their proteins in the 
endosperm (Takaiwa et al. 1995).  
Pea (Lau and Sun 2009) and tobacco seeds (Frega et al. 1991) are equal in regard of protein 
content (approx. 25 % of TSP), but different in yield of seeds per hectare. 2.7 – 3.7 tons 
pea seeds was harvested in Germany  per hectare field and even more in greenhouse is 
possible (5 tons per hectare (Mikschofsky and Broer 2012)). Tobacco yields 1.1 tons per 
hectare seeds (Giannelos et al. 2002), which is up to 30 % less. Because of this pea would 
be the ideal expression platform for VacZP3-P expression. But whether the protein 
content (Stöger et al. 2002) nor yield per hectare should be the major factor to choose 
the expression system. Pea is not practical yet, because of low accumulation level. For 1 
mg VacZP3-P at least 100 kg pea seeds are necessary. The much better accumulation of 
VacZP3-P in tobacco seeds overcomes the lower biomass per hectare disadvantage. In the 
best case 4.2 and 33 g tobacco seeds are sufficient to yield 1 mg VacZP2 and VacZP3-P 
vaccine, respectively.  
Comparison between seed-based and constitutive expression  
In comparison to leaf-based expression under the control of the CaMV35S promoter, 
seed-specific expression of VacZP2 in tobacco seeds was increased up to 2600-times. The 
improvement to carrot cells was a little less, but with 450-fold still very high. Seed-specific 
expression could lead to higher accumulation level, than leaf-based expression (Jaeger et 
al., 2002; Nausch et al., 2012a). The plant organ could have a big influence on protein 
stability. Petruccelli et al. 2006 detected a proteolytic cleavage of the γ chain of a 
monoclonal antibody in tobacco leaves, but not in seeds. Due to the desiccant nature of 
the mature seed and the function as storage organ, proteolytic activity is decreased 
(Müntz 1998; Stöger et al. 2005), so that recombinant proteins can be stored at room 
temperature for several months without significant loss (Boothe et al. 2010; Benchabane 
et al. 2008; Stöger et al. 2005). The pea vicilin storage protein was constitutively expressed 
in leaf and seed of tobacco. Despite of similar RNA levels the accumulation was 50 – 100-
times higher in seeds than in leave tissue (Kermode 2006). Besides the plant organ, the 
discrepancy of VacZP2 expression between tobacco leaf and seed could be the promoter. 
Jaeger et al. 2002 increased the expression of the murine scFv G4 from 1 % of TSP in 
Arabidopsis seeds to 12.5 % of TSP by using the arcelin5-I instead of the CaMV 35S 
promoter. The choice of an appropriate promotor to drive protein expression can 
influence protein level significantly (Stöger et al. 2002). 
Transient expression 
The transient expression in N. benthamiana is known as high production platform for 
recombinant proteins. Marillonnet et al. 2004 accumulated to up to 5 gGFP/kgFW in 
Nicotiana benthamina after transient expression. For VacZP2 we achieved 0.11 
gVacZP2/kgFW. In comparison to Marillonnet et al. 2005 with the same method this is quite 
low. Nevertheless, our result is in the range of other MagnICON expressed antigens like 
the isoform of human glutamic acid decarboxylase (GAD65; 0.23 gGAD/kgFW) and human 
epithelial mucin fused to heat-labile enterotoxin (LTB-MUC1; 0.09 gLTB/kgFW), respectively 
(Merlin et al. 2016; Pinkhasov et al. 2011). Accumulation of VacZP3-P (0.011 gVacZP3-P/kgFW) 
was even 10-fold lower. To the best of my knowledge, no data is published such a low 
level of MagnICON. Other studies expressed a high amount of recombinant protein in 
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N. benthamiana  with the same system (Ponndorf et al. 2016; Nausch and Broer 2016b; 
Nausch et al. 2012a). In comparison to them it seems, that VacZP2 and VacZP3-P are 
unstable or have a low expression rate. The major factor for this is the sequence, as well 
as at nucleotide and amino acid level. The sequence could be responsible for reduction in 
translation rate, because of inefficient codon optimization (Nausch and Broer 2016b). 
Furthermore, the sequence could exhibit protease sites. Since the magnitude of 10-fold 
difference in accumulation level between both ZP vaccines is the same in transient 
tobacco leaves and transgenic tobacco seeds, the hypothesis is supported. VacZP2 could 
have less negative impact on the hosts expression machinery and/or exhibit higher 
resistance to proteases than VacZP3-P, leading to higher accumulation (Michaud et al. 
1998). 
The content of VacZP2 and VacZP3-P in the freeze-dried and pulverized leaf material not 
decreases significantly for at least 35 and 21 weeks, respectively. The content stability of 
both ZP vaccines is similar to the transplastomic expression of CTB-VP1 (a polio antigen; 
Chan et al. 2016) and CTB-ESAT6 (a tuberculosis antigen; Lakshmi et al. 2013). Both were 
stable for up to 32 and 24 weeks at room temperature after freeze-drying, respectively. 
Seed versus transient expression   
Seed-specific expression in tobacco of VacZP2 and VacZP3-P under the control of the 
arcelin-5-I promoter showed the highest accumulation level of all tested stably 
transformed approaches. With 0.25 and 0.03 % of TSP, they show a typical accumulation 
level for biopharmaceuticals expressed in plants, ranging between 0.1 – 0.01 % of TSP 
(Doran 2006), respectively. But expression in the transient system increases the amount 
of VacZP2 and VacZP3-P per TSP to up to 16 and 12-fold. Because of the viral replicon and 
the resulting higher expression rate, the transient expression is able to deliver high 
protein yields in a short period of time (Xu et al. 2012), which is an advantage over stable 
transformation strategies. It was presumed that the sensitivity of the VacZP vaccines limit 
a higher accumulation in tobacco seeds, the enourmous expression rate of the transient 
expression system might compensate a protein degradation in long-term (Nausch et al. 
2012a). Expression of the Interleukin-6 via the same transformation vector (pICH29912) 
we used, exhibited up to 64-times higher accumulation than in tobacco seeds (Nausch et 
al. 2012a). Vaquero et al. 2002 expressed more of T84.66/GS8 diabody in a transient 
expression approach than with stable transformed tobacco plants.  
In some cases stable transformed plants have even higher yield of recombinant protein 
than transient expression (Merlin et al. 2016; Gecchele et al. 2015), in addition to that, 
these systems have advantages in product costs and scalability (Xu et al. 2012). Especially, 
when taking into account that the proportion of recombinant protein can be increased 
via breeding (Nausch et al. 2012b; Hühns et al. 2008; Jaeger et al. 2002). 
The seed-based expression of the VacZP vaccines has a big advantage over leaf-based 
transient expression, when it comes to storage of unprocessed transgenic plant material. 
The desiccated nature of mature seeds, together with the low abundance of active 
proteases in seed tissues during dormancy, prevent extensive proteolysis and promote 
long-term stability of proteins in planta (Stöger et al. 2000; Fiedler and Conrad 1995). This  
allows a complete separation of cultivation and processing/purification process without 
additional conservation (Boothe et al. 2010). Seeds have a simpler protein composition 
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than vegetative tissue, which could result in fewer purification steps and lower costs 
(Twyman et al. 2005; Stöger et al. 2002). Leaf tissue have to be conserved or processed 
immediately after harvest (Xu et al. 2012). Transient expressed VacZP2 and VacZP3-P in 
leaf material was freeze-dried and stabilized the protein content for at least 21 weeks. 
This conservation method is an additional cost point in the downstream process and the 
stability of VacZP3-P content was much lower than in seeds. The low nicotine present in 
the tobacco seeds allows oral application without expensive purification (Rossi et al. 2003) 
in contrast to Agrobacterium-contaminated and highly toxic tobacco leaves in the 
transient expression system (Rosales-Mendoza et al. 2017). 
The advantage of the transient expression system MagnICON against the stable 
seed-based system is the possibility to shortly react to sudden demand of recombinant 
protein. But production capacity is limited by the technical process of plant 
transformation. Due to the publication from Hamorsky et al. 2013 we assume that 
Kentucky Bioprocessing, LLC, a large-scale transformation factory, would be able to 
produce around 950 g VacZP2 and 77 g VacZP3-P in 12 weeks. The costs and efforts are 
higher than producing this amount of recombinant vaccine in the tobacco seed-based 
system. Here only 3.6 (VacZP2) and 2.4 hectar (VacZP3-P) would be necessary, presuming 
a tobacco seed yield of 1.1 ton seed per hectar (Hernández-Velázquez et al. 2015; 
Giannelos et al. 2002). Provided that a grow on open field is approved, seed-based 
production of both VacZP vaccines become an attractive alternative to transient 
expression, when short reaction time is not mandatory. 
Due to the high alkaloid content in the Nicotiana leaves (200 mg/kgFW) (Rossi et al. 2013), 
the ZP vaccines generated via transient expression must be purified for administration. It 
is not suitable for oral vaccination (Daniell et al. 2009). In contrast to this, tobacco seeds 
contain much less (2 µg/kgFW) nicotine (Rossi et al. 2013) and can be used for oral 
vaccination (Rossi et al. 2014), which could save money in the downstream processing 
due to a simpler process (Nausch et al. 2012b; Ramessar et al. 2008). If a purification is 
desired, the purification process could be simplified, because of a lower profile of the seed 
protein (Lau and Sun 2009; Jaeger et al. 2002). 
Since the MagnICON platform offers the opportunity of short available 
biopharmaceuticals (Gleba et al. 2005), we decided to produce VacZP2 and VacZP3 P in 
Nicotiana benthamiana to rapidly gain enough vaccine material for animal testing via 
parenteral injection. This process is more cost intensive than seed-based production, due 
to high effort of infiltration and conservation by freeze-drying. Building up a seed-based 
VacZP expression takes around 6 months longer in the beginning, but once established it 
costs only a few amounts of money. If the factors of up-scaling and oral vaccination 
become more important, than the use of the seed-based expression system should be 
considered. 
Plant versus E. coli, yeast, CHO cells 
The expression of VacZP vaccines were performed in plants, because of special features 
in comparison to other pro- and eukaryotic expression systems. Plants have similar 
post-translational modifications like animals and humans with minor difference in protein 
glycosylation (Fischer and Emans 2000). This glycosylation pattern could contribute to a 
native epitope of an VacZP antibody, which seems to be critical for sterilizing  (Hardy et 
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al. 2003) and due to plant specific α1,3 fucose and/or β1,2 xylose may also increase 
immunogenicity of the vaccines (Matoba 2015; Bosch and Schots 2010; Saint-Jore-Dupas 
et al. 2007). In contrast, E. coli has no glycosylation and yeast very different pattern in 
comparison to mammals. The mannan-type N-glycans of yeast are more immunogenic 
than plants and can lead to unwanted reactions after administration (Gomord and Faye 
2004).  
Purification from plant cells is much simpler and saver, than from CHO cells, because of 
not hosting animal and human pathogens (e.g. HIV, hepatitis viruses) (Doran 2000). This 
lack of screening has a favorable effect on production cost. These cost are in general lower 
than CHO cell expression (Fischer and Emans 2000). Because of the independence from 
fermenters transgenic plants are easy to scale up and to propagate, which is a big 
advantage over microbial and mammalian cell cultures (Fischer and Emans 2000).  
Both VacZP proteins exhibited instability in N. benthamiana in vivo and in vitro. In case of 
VacZP3-B this was also observed during bacterial expression. After extraction VacZP3-B 
was stable but degradation started when plant protein extract was added. To avoid 
degradation of plant-derived VacZPs in and ex planta the targeting to an alternative 
intracellular compartement (e.g. plastids, vacuole) (Santos et al. 2016) or fusion to an 
stabilizing agent (Lau and Sun 2009) should be taken into account. 
5.2 VacZP2  
The highest yield of around 1 µg per mg dry weight for VacZP2 was observed after 
transient expression in N. benthamiana. Though the amounts of our ZP vaccines produced 
in plants are low compared to other plant made recombinant proteins, to gain 100 µg 
∆pZP2 only 2 g of fresh plant material is sufficient. To gain the same amount from the 
natural source, up to 227 and 104 pig ovaries are necessary, respectively (Hasegawa et al. 
1991; Hedrick and Wardrip 1987; Dr. K. M. Frank, SCC, Billings, MT, personal 
communication). A dose of PZP, containing porcine ZP2, ZP3 and ZP4, is 65 – 100 µg for a 
wild horse. 
It is still questionable, whether sufficient amounts of pig ovaries are available for 
immunization of great numbers of small mammals like dogs, cats or rodents. In addition, 
the plant made vaccine is free from contamination with other proteins present in the 
ovary that lead to inflammation in many recipients (Gupta et al. 2014). 
Infiltration of pICH-VacZP2 with the MagnICON vector elicited strong phenotypical 
changes on N. benthamiana leaves. This observation is common (Huy and Kim 2017; 
Nausch and Broer 2016b; Hamorsky et al. 2015; Pinkhasov et al. 2011; Huang et al. 2006), 
and not referable to the transgenes. But leaves infiltrated with a ZP construct were more 
healthy compared to the empty vector control (Nausch and Broer 2016b). It still remains 
unclear, whether the ZP vaccines are harmful to the plants by themselves or viral 
replication exhaust plant translation machinery. However, no phenotypical saliences in 
plant growth were observed in the stable transformed plants, which most likely make a 
harmful effect of VacZP2. 
The quality (integrity) of VacZP2 protein via MagnICON expression was analyzed in 
Western blot analysis. Antibodies binding at the N-terminal CTB and the C-terminal his-
tag demonstrate the presence of the complete fusion protein, respectively. The fusion 
protein was purified via Ni-NTA purification. In the elution fraction besides VacZP2 CTB 
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monomers were always detectable. Gentle and protease protected isolation conditions 
had no effect on the occurrence of CTB monomers in the elution fraction. A co-purification 
of free CTB via Ni-NTA columns is probable  (Dertzbaugh and Cox 1998). But it is also 
possible, that CTB monomers assemble with VacZP2 monomers to pentamers and are co-
purified via his-tag.  
Directly after crude protein isolation from lyophilized N. benthamiana leaves, VacZP2 is 
degraded. Responsible for this might be plant proteases. This is supported by the fact, 
that low temperature or protease inhibitors retard this in vitro reaction. It can be excluded 
that oligomerization of VacZP2 is the reason for the fading of the monomer signal, 
because of a non-increasing signal for oligomers and stopped signal fading after 
purification.  
VacZP2 is able to form pentamers via the CTB domain. This was verified by mono-
sialoganglioside GM1 binding assays (Dakterzada et al. 2012; Merritt et al. 1994; Hardy et 
al. 1988). Our results indicate that the majority of measured CTB is pentameric 
(unpublished data), what is conform with the auto-assembling ability of CTB (Yasuda et 
al. 1998). Due to other CTB fusion protein studies (Huy and Kim 2017; Nochi et al. 2007), 
it could be assumed that the oligomerization ability of our CTB-ZP fusion protein is also 
necessary for a possible mucosal delivery.  
The detection of VacZP2 in the lectine blot and a slightly heavier monomer protein 
(approx. 35 kDa) than calculated (32.2 kDa) proofs an occupation with N-glycans. Due to 
four N-glycosylation sites in the VacZP2 sequence a macroheterogenic in N-glycosylation 
(Jones et al. 2005) was expected, which would lead to VacZP2 variants of alternating 
weight between 35 – 44 kDa. This could explain the occurrence of a second slightly heavier 
band (approx. 41 kDa) of the VacZP2 monomer. A variation in glycosylation of 
heterologous glycoproteins in plant expression systems is very common (Gomord and 
Faye 2004; Bardor et al. 2003b), so that two VacZP2 monomer variants are not unusual. 
This inconsistency of site occupation was previously observed in tobacco (Hamorsky et al. 
2013) and rice (Kajiura et al. 2013; Yuki et al. 2013), which resulted in a non- and once 
glycosylated CTB with a difference in mass between 1.5  and 3 kDa (Mikschofsky et al. 
2009a; Matoba et al. 2009; Mishra et al. 2006). Plant-based CTB expression in other 
studies observed a macroheterogeneously glycosylated CTB at Asn4 (Hamorsky et al. 
2013; Kajiura et al. 2013; Yuki et al. 2013; Mikschofsky et al. 2009a; Nochi et al. 2007), 
what could explain the lighter (12 and 15 kDa) bands. The third band (18 kDa) could 
originate from microheterogenous occupation (Jones et al. 2005) of Asn4 or glycosylation 
at Asn93, a second potential Asn-X-Thr/Ser sites (Kornfeld and Kornfeld 1985). But 
occupation of Asn93 seems less probable (Matoba 2015) due to subsequent proline after 
the sequon (Gavel and Heijne 1990; Bause 1983). With our results, no exact statement is 
possible, which one of the four Asn-X-Thr/Ser sites (Kornfeld and Kornfeld 1985) is 
occupied. Two are situated in the CTB domain and two in the pZP2 domain. However, 
due to occurring free glycosylated CTB molecules between 12 and 18 kDa when VacZP2 is 
expressed, a glycosylation of the CTB domain within the VacZP2 fusion protein could be 
assumed. Furthermore, the occupation of the pZP2 domain could be assumed, because 
the plant-derived pZP2onlyP is also glycosylated and a likewise occupation of the 
N-glycosylation sites is possible. 
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Free CTB molecules between 12 and 18 kDa were detected, despite of protective protease 
inhibitor mix and cooled and gentle isolation of VacZP2. That indicates a possible in vivo 
instability at protein or RNA level (Stöger et al. 2002). In regard to protein instability, free 
CTB molecules could represent C-terminally truncated VacZP2 molecules, like the 
CTB-MPR649-684 from Matoba et al. 2009. Similar to this study, the rest of our fusion protein 
(antigen, TT, histidine tag and SEKDEL) could not be detected via anti-histidine antibodies. 
Maybe it was degraded by exopeptidases beginning from the C-terminus of VacZP2 and 
CTB is a leftover, because it is known for their stability in harsh environments (Zhang et 
al. 1995). The phenomenon of free CTB molecules was observed by other studies in 
transplastomic tobacco (Chan et al. 2016; Lakshmi et al. 2013) and N. benthamiana in an 
ER-targeted approach (Tien et al. 2017; Kim et al. 2016; Matoba et al. 2009; Huckauf J., 
unpublished data). Another possible explanation could be a split in the Glycin-Proline-
Glycin-Proline (GPGP) hinge region between CTB and antigen by an uncharacterized plant 
endopeptidase (Matoba et al. 2009). But this observation is inconsistent with other CTB-
based vaccines using GPGP linker expressed in transplastomic tobacco (Su et al. 2015a; Su 
et al. 2015b; Kwon et al. 2013b; Boyhan and Daniell 2011; Davoodi-Semiromi et al. 2010; 
Verma et al. 2010; Ruhlman et al. 2007). In this study it was not possible to determine a 
responsible N. benthamiana specific protease via MEROPS protease database, which is 
cutting in the region of the GPGP linker and bring an explanation for CTB monomer.  
But free CTB molecules could also be a production of transcript instability or an 
unexpected alternative transcription. If there is a separate transcript leading to free CTB 
monomers a mRNA fitting to detected proteins would be detectable. Anti-CTB Northern 
blot analysis detected RNA (approx. 483 nt) longer than CTB domain + GPGP linker (390 
nt) and much shorter than the smallest viral mRNA coding for the VacZP2 fusion protein 
(1178 nt). One possibility could be an unwanted stop during vacZP2 transcription from 
the gen inside the nucleus or the viral replicon in the cytosol. But no transcription stop 
signal within the sequence of vacZP2 was found to describe such small RNA fragments. 
The consequences of free CTB in the plant protein extract are discussed in the last chapter. 
VacZP2 was parenterally delivered in female mice and hamsters and show an immune 
reaction. In mice immunization show an anti-VacZP2 immune reaction already after 
priming, which is a typical course (Janeway and Murphy 2012; 8th ed.; p. 24). The titer 
increases with additional booster, which is an effect of the immunological memory (Prisco 
and Berardinis 2012; Sallusto et al. 2010). Interestingly, the anti-pZP2onlyP titer 
significantly reduces after second boost, which could be a sign of too short boost interval 
resulting in terminally differentiated memory T cells with decreased capacity to 
proliferate (Sallusto et al. 2010). The reduction after the second boost in antibody titer in 
the same mice strain and same time interval was also observed by Gupta et al. 2013. That 
booster injections doesn’t lead to an increase of antibody titer is not specific for 
recombinant ZP vaccines in mice (Mahi-Brown et al. 1992; Keenan 1991; Wood 1981). 
Especially, the vaccination of hamster with PZP did not increase the antibody titer after 
third boost (Hasegawa et al. 1992). This is consistent to our results in hamster with 
VacZP2. A optimization of the priming-booster regime could intensify the immune 
reaction (Castiglione et al. 2012) and longer periods of time between booster injections 
could elicit higher amplification (Sacco et al. 1983). But it could also be possible that a 
limit was reached like in many other ZP studies (Kitchener et al. 2009b; Kitchener et al. 
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2002; Hasegawa et al. 1992; Hasegawa et al. 1991; Keenan 1991; Sacco et al. 1981; Wood 
1981). 
Interestingly we observed an immune reaction without adjuvant in mice. The level of 
antibodies against the antigen domain pZP2 is actually equal to vaccination with adjuvant 
after the second boost. Immunization studies of PZP without adjuvant resulted in a poor 
(Mahi-Brown 1985) or no (Bhatnagar et al. 1989) immune reaction and it must be given 
with an adjuvant (Kirkpatrick et al. 2011). This could be an indicator for good intrinsic 
immunogenicity of VacZP2 by a sophisticated vaccine design (De Groot, Anne S. et al. 
2010), maybe triggered by the fused adjuvants CTB (Chan et al. 2016) and TT (Fraser et al. 
2014; Panina-Bordignon et al. 1989), the plant specific glycosylation pattern (Bosch and 
Schots 2010; Matoba et al. 2009; Bardor et al. 2003a; Kurosaka et al. 1991) or plant-
derived adjuvant compounds (Rosales-Mendoza and Salazar-González 2014). Besides this, 
the integration of the di-lysine linker, a cleavage site of the cathepsin B protease (Sarobe 
et al. 1993; Takahashi et al. 1988), could improve the antigen processing of VacZP2. The 
feature of no need for an adjuvant was shown before with other CTB fusion proteins 
(Kwon et al. 2013a; Ruhlman et al. 2007) and may dispense the necessity of an extra 
formulation step of the plant material to sterilize animals.  
Antibodies against the pZP2 domain, proven by anti-pZP2onlyP ELISA, revealedthat the 
design of the VacZP2 fusion protein enables an appropriate antigen presentation in the 
animal. This is a requirement of the formation of sterilizing antibodies. How much the 
ratio of pZP2 antibody to antibodies of pZP2 fusion partners is could not be determined. 
A comparison by serum dilution is invalid because no correction factor or unifying 
standard was used in both assays. How much antibodies binding to a immobilized antigen, 
which is measurable by the extinction, depends on the affinity (Heinrich et al. 2010). This 
affinity, composed of the dissociation constant and the kinetics (Heinrich et al. 2010), was 
not determined as correction factor.  
The same counts for the comparison between mice and hamster. It is not accurate to say 
in which animal VacZP2 is more immunogenic, because the quality of the immune 
response resulting in a reduced fertility is relevant (Jones et al. 1992). But a differing 
immunogenicity of VacZP2 could be assumed, because of different genetic background 
and the connected immune system (Dunbar et al. 1994). 
A subsequent mating experiment to show how contraceptive VacZP2 in FvB mice is, failed 
due to highly aggressive female mice. They have bitten males and killed their offspring, 
although this they were acclimated to their housings (unpublished data). A repeat with 
more calm mice, maybe another mice strain, could answer the question of spaying 
efficacy of VacZP2 in mice. 
VacZP2 show an impact on hamster fertility. This could originate from an included epitope 
(5H4) with known contraceptive effect in vitro (Hasegawa et al. 2002; Hasegawa et al. 
2000; Shigeta et al. 2000; Hasegawa et al. 1995) and in vivo (Miller et al. 2000). The effect 
on contraception is not significant and lower than observed with native, porcine ∆ZP2 
(Hasegawa et al. 1992; in this paper designated as ZP4). The quality of the VacZP2 
antibodies should be approved by IVF (in vitro fertilization) assay. This would help to find 
out whether the antibody titer is under the threshold of blocking sperm-egg contact or 
the fertilization-relevant epitopes on the hamster’s ZP are not occupied. First, if the titer 
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is to low, stronger adjuvants (Bagavant et al. 1994) like complete Freund’s adjuvant (CFA) 
used by Hasegawa et al. 1992 during hamster immunization or a more optimal dose could 
be a solution (Mahi-Brown et al. 1992). Second, if the relevant ZP region is not covered by 
VacZP2 antibodies to block sperm from fertilizing, the sequence design of VacZP2 should 
be optimized to support an appropriate antigen processing inside hamster’s leukocytes, 
meaning making 5H4 and other unknown epitopes available. This measures includes the 
prevention of interfering plantal PTMs, like epitope covering glycan residues (Matoba 
2015; Boes et al. 2015), and positive sequence adjustments, like the introduction of 
spacers between the ZP epitopes or fusion of other promiscuous epitopes (De Groot, Anne 
S. et al. 2010). 
Vaccination with VacZP2 + Polygen seems to have a transient effect on fertility. This is 
supported by histological analysis of hamster ovaries (unpublished data). The ovar 
exhibited no unnormal atresia or inflammation (Dr. J. Schön, FBN Dummerstorf, personal 
communication), having a healthy pool of follicles able to develop fertile eggs. In contrast, 
the vaccination of hamster with PZP + CFA (Hasegawa et al. 1992) and recombinant 
Hamster ZP (Koyama et al. 2005) causing huge ovary degeneration in the follicle pool, 
leading to permanent sterility by cytotoxic immune response. It is possible, that VacZP2 
cause no degeneration due to a humoral immune response, where only antibodies against 
the egg are generated. Which of the immune reaction is triggered, is mainly controlled by 
adjuvants (Vogel 2000) and it is possible, that CTB (Baldauf et al. 2015) and TT (Panina-
Bordignon et al. 1989) are also involved in eliciting a humoral response. Bonnet monkey 
ZP3 caused with CFA profound follicular atrophy in marmosets, but not with SPLPS 
(Upadhyay 1989). For VacZP2 + Polygen subsequent analysis about the type of immune 
response (Th1 or Th2) should be conducted. Another possibility, why no follicles were 
negatively affected, could be that anti-VacZP2 antibodies are not affine to the ZP of early 
stage follicles. In this case they are not able to degenerate the whole follicle pool (Rankin 
et al. 2001). This is supported by the fact, that pZP2 epitopes are presented not until late 
stages of follicle development (secondary and tertiary follicle) in hamster (Hasegawa et 
al. 1992).  
VacZP2 is still in a concept phase and thus not economical. One reason for this is the low 
level of contraception. The high immunogenic effect of VacZP2 detected in hamster 
should lead ideally to a block of fertilization at least for 50 % of tested animals and 
subsequently eliciting a long-lasting protection. Since first was not complied in our 
experiment, second is obsolete. The next step should be the improvement of the immune 
response quality by dose, formulation and prime-booster regime studies, to get equal to 
native pZP2 in hamster. Not before the potential of contraception of VacZP2 in hamster 
has been exhausted, it is difficult to conclude how much VacZP2 should be produced to 
sterilize a specific number of animals. So, besides the immunogenic efficacy the 
production platform defines the costs. The plant production system determines the speed 
and effectivity of production due to yield per biomass, time of production cycles, 
storability and costs of cultivation and purification. We only tested the transient 
expression system to produce mid amounts of VacZP2. The seed system could become 
attractive, when accumulation level is increased. The advantages are a long storability 
without special conservation methods, great scalability and proper for oral application. 
But and economic comparison between transient and seed-based expression system 
could not be done in this work. But expression of VacZP2 in carrot cells and tobacco leaves 
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under the control of the CaMV35S can be designated as unpractical in this setting. To gain 
1 mg of VacZP2 at least 1.9 kg carrot callus is required. To gain 1 mg vaccine 30 kg tobacco 
leaf material has to be harvested. 
5.3 VacZP3-P 
The production of VacZP3-P was best implemented with transient expression system. 
Although the yield of VacZP3-P is low compared to other recombinant plant made 
biopharmaceuticals, only 18 g of fresh N. benthamiana for 100 µg ZP3 are sufficient. We 
assume, that up to 104 pig ovaries are necessary to receive the same amount (Hasegawa 
et al. 1991; Hedrick and Wardrip 1987; Dr. K. M. Frank, SCC, Billings, MT, personal 
communication with). It is obvious, that recombinant ZP vaccines could overcome limited 
availability of pig ovaries to immunize a large number of mammals (Gupta 1997). The 
plant made VacZP3-P is free from contamination with other proteins leading to 
inflammations in the ovary (reviewed in Gupta et al. 2014). 
Similar to the transient expression of VacZP2, the expression of VacZP3-P causes massive 
leave withering. But leaves infiltrated with empty vector showed even higher damage, 
too. This relieves VacZP3-P from being harmful to the plant. This is supported by the 
expression in pea and tobacco via pARC-VacZP3-P, where no special phenotype was 
exhibited. Exception was tobacco event 144 with a reduced seed production and highest 
VacZP3-P accumulation level. Our phenotype could also be addressed to somaclonal 
variations (Kaeppler et al. 2000). Further studies show that only 10 % of the offspring still 
have this phenotype. The other 90 % show no phenotype but have similar accumulation 
levels (Jana Huckauf, personal communication). 
The integration of VacZP3-P was verified by Western analysis targeting the N-terminal 
CTB and the C-terminal his-tag. But similar to VacZP2 free CTB molecules occurred as 
well as in the crude protein extract and the elution fraction. So, there were the same 
problems to quantify VacZP3-P via anti-CTB ELISA and isolating VacZP3 from free CTB 
molecules. 
VacZP3-P is also sensitive to plant proteases after isolation and degrades without 
protection by cooling or protease inhibitors. The reason for degradation should lay within 
plant protein extract. This is supported by the degradation of purified bacterial VacZP3-B 
by crude protein extract from tobacco.  
VacZP3-P pentamer formation was also proven by GM1 binding assay like VacZP2-P. That 
means VacZP3-P is due to the fusion of CTB able to bind to many cell types (Sánchez and 
Holmgren 2008), even gut epithelia cells. CTB enables an oral route through the M-cells 
(Nochi et al. 2007). Thus, amount detected in anti-CTB and GM1 binding assay are not 
significantly different, a pentamer formation of the majority of CTB molecules could be 
assumed. 
VacZP3-P is N-glycosylated. The difference in size of 17 kDa between the unglycosylated, 
bacterial VacZP3-B to the plantal VacZP3-P could be explained by the occupation of 
N-glycans. Due to free, glycosylated CTB molecules, an occupation within the CTB domain 
like VacZP2 could be assumed. But because of the size other glycosylation sites within the 
antigen domain should be occupied. Which of the 5 sites offsite from CTB is occupied 
could only be cleared by mass spectrometrie. 
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It is interesting, that the phenomenon of free CTB molecules occurs as well as by VacZP3-P 
and VacZP2 expression. And it is still not clear at which level (RNA/protein) the trigger for 
CTB formation is situated. Thus, no equal sequence or motif in the N-terminus of both ZP 
domains were found, it is more likely that the equal coding region or amino acid sequence 
of CTB and GPGP linker is responsible for causing a transcriptional/translational error and 
proteolytic degradation, respectively. This hypothesis is supported by other studies using 
CTB-GPGP combination (see discussion VacZP2). 
The in vitro degradation of purified VacZP3-B by plantal crude protein extract created no 
CTB monomers. For plantal CTB formation it means, that this phenomenon supports both 
in vivo CTB formation by plantal ER proteases before cell breakdown and an unwanted 
interruption of the transcription/translation to the fusion protein. Both processes happen 
only in intact plant cells. The absent formation of novel CTB monomers during in vitro 
degeneration of plantal VacZP3-P would support it. How free CTB influences the 
immunogenicity is discussed in the last chapter. 
The plant-made VacZP3-P elicited a good immune response in BALB/c directly after 
priming and increased after each booster injection significantly even at low dosages. 
Before the second boost, higher doses show no significant difference on antibody 
formation. This is the first time, that such small amounts of 2 µg porcine ZP vaccine were 
tested in mice and show immune response (Sacco et al. 1981; approx. 3.3 µg). However, 
after second boost, group with the highest dose (21 µg) exhibit a significantly higher 
antibody titer against VacZP3-P. The 1.25-fold increased in antibody titer after second 
boost with 21 µg were realized by a 10- fold higher dose in comparison to 2 µg. If this little 
difference in antibody titer is critical for sterilizing or could be neglected could only be 
evaluated by subsequent mating experiment (Kirkpatrick, History of PZP, unpublished 
data). In our experiment, there was no direct connection between anti-VacZP3-P antibody 
titer and infertility. But it needs to be taken into account, that the titer against the 
sterilizing pZP3 domain was not measured and that the anti-VacZP3-P titer may include 
also antibodies against CTB, TT and his-tag. Due to the VacZP2 titer results, where high 
titer against VacZP2 also exhibited high titer against the antigenic pZP2 domain, we 
assume the same for VacZP3-P titer. Some individuals with high VacZP3-P titer became 
pregnant others didn’t or exhibited a reduced litter size. In some studies there are 
correlations between antibody titer and impact on fertility (Lloyd et al. 2003; Hardy et al. 
2002b; Govind et al. 2002; Sadler et al. 1999; Liu et al. 1989; Millar et al. 1989; East et al. 
1985), in others don’t (Clydesdale et al. 2004; Lai 2004; Lloyd et al. 2003; Hardy et al. 2003; 
Srivastava 2002; Martinez 2000) or the effect is inverse (Lo et al. 2011). This phenomenon 
could not be limited to a specific type of vaccine or animal species. The qualitive nature 
of antibodies seems more significant than absolute titer (Hasegawa et al. 2002; Jones et 
al. 1992; Sacco et al. 1981).  
Even though in our approach no connect between titer and fertility was observed, 
statistically a direct connection between dose and the number of offspring is visible.  It 
could be possible that we increase the contraceptive effect on mice after VacZP3-P 
immunization by increasing the dose to an optimum. An increase of VacZP3-P dose could 
enhance the sterilizing effect. The optimal dose for native PZP in mice was determined 
with 137 µg (Sacco et al. 1981), which is more than 6-times higher. But the optimal dose 
depends on the vaccine itself and should be determined by further experiments. 
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The mating experiment showed a tendency of impact on mice fertility by VacZP3-P. This 
is supported by a reduction of 43 % of offspring in the group receiving 21 µg VacZP3-P 
(animals failed to conceive are included). This is much less than the reduction of mice litter 
size of 74 and 90 % Clydesdale et al. 2004 and Gupta et al. 2013 obtain with their 
recombinant porcine ZP3 vaccines, respectively. In our approach, the reduction of the 
litter size is not significant to the control group (p = 0.06, Tukey-HSD; p = 0.085, 
Bonferroni test), which is a similar observation like Sacco et al. 1981 made with native 
PZP, which contain pZP3. This group discussed that antibodies against pig zona pellucida 
maybe doesn’t bind to murine fertilization-relevant epitopes, but this is disproved by the 
recombinant vaccines from Clydesdale and Gupta. A second experiment with VacZP3-P 
with the same setting reproduced the sterilizing effect to BALB/c mice (Dr. Huckauf, 
personal communication). Although our approach used the same porcine ZP3 antigen like 
Clydesdale et al. 2004 and Gupta et al. 2013 many things are different: vaccine design, 
expression system, mice strain and adjuvant.  
VacZP3 uses other fused adjuvants than Gupta et al. 2013 to increase the immunogenicity. 
Clydesdale et al. 2004 and Gupta et al. 2013 expressed their vaccine in E. coli and simian 
kidney fibroblast cells, respectively, which results in different PTMs (post translational 
modifications). We used BALB/c mice like Clydesdale et al. Gupta immunized FvB/J mice 
with the synthetic polymer adjuvant PetGel A. Clydesdale et al. 2004 used Complete 
Freund’s adjuvant (CFA or FCA), the strongest adjuvant, which could cause unwanted 
inflammations at the infection site (Sacco et al. 1989) or the ovar  (Gupta et al. 2013; Frank 
et al. 2005; Upadhyay 1989). In our experiment the co-polymer adjuvant Polygen was 
used, a strong adjuvant with proven record (Wernike et al. 2017; Mikschofsky et al. 2009b; 
Wegelt et al. 2009). These differences make it difficult to determine one factor, which 
could be responsible for the lower contraceptive effect in our experiment setting. 
Additionally, Polygen as adjuvant for ZP vaccination was used for the first time. But  The 
much lower efficacy of TT-KK-ZP3 from Gupta et al. 2013 in our setting, other mice and 
other adjuvant, is exemplary for the high influence of genetic animal background 
(Bagavant 1997; Lou et al. 1995; Rhim et al. 1992) and adjuvant (Gupta et al. 2011; 
Upadhyay 1989) a on contraception.  
Although we used a similar size per group (Gupta et al. 2013; Hardy et al. 2004; Clydesdale 
et al. 2004; Sacco et al. 1981), the spaying effect within our testing groups were very 
variable. Some individuals show normal litter size other only reduced ones. This 
contributed to a high standard deviation leading to a fail of significance. It is not clear, if 
an increase of group sizes vaccinated with VacZP3-P would sharpen the statistics. At this 
point VacZP3-P only affects the fertility of special individuals, although all mice threated 
with 21 µg vaccines respond homogenous. But this observation occur also in other BALB/c 
mice ZP immunization studies (Hardy et al. 2008; Hardy et al. 2004; Jackson 1998), though 
the amount of responders was higher than 50 %. This is the reason existing antibodies 
decrease fertility or remain uneffective is still unclear. But the individual hormone profiles 
of the female mice could vary during the experiment and could have an influence on the 
ZP structure (Barber and Fayrer-Hosken 2000). In further experiments in vitro fertilization 
should be conducted to prove an anti-VacZP3-P antibody binding to the egg. This is the 
requirement for shielding the sperm receptor on the egg from the sperm contact.  
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The question whether VacZP3-P is economic at this point, could be answered like for 
VacZP2. The contraceptive effect on mice and the accumulation level in the transient 
expression system is yet to low. Both factors have to be increase with further work. It 
could also be possible that one factor limits the other. If this occurs, a change of 
expression system or animal species should be considered. It was shown, that PZP is not 
very potent in mice (Martin et al. 2006; Sacco et al. 1981) and kittens (Gorman et al. 2002; 
Jewgenow et al. 2000), but effective in marsupials (Kitchener et al. 2009b; Kitchener et al. 
2002) and ungulates (Frank et al. 2005). But a final evaluation should be done after 
optimization at production and application side. The first results are promising to do so.  
5.4 Comparison between VacZP2 and VacZP3-P 
A final verdict whether VacZP2 or VacZP3-P is more contraceptive and should be favored 
to spay mammals, is not possible at this point. The accumulation level in plant expression 
systems clearly supports VacZP2. In the transient expression system, where both vaccine 
performed best, VacZP2 accumulated over 11-fold higher than VacZP3-P. But in regard to 
the efficacy in animals a comparison is vague. Both prove their immunogenic potential in 
mice, but for VacZP3-P immunization we had to use BALB/c mice, a different inbred strain 
than used with VacZP2. A comparison of the immune reaction of two mice strains with 
different MHC H2 haplotypes is invalid. It is known that the genetic background influences 
the immunogenicity (Hardy et al. 2003; Hardy et al. 2002b; Lou et al. 1995a). Because of 
this barrier, we cannot say whether VacZP2 or VacZP3-P is more immunogenic. We used 
a different mice strain to test VacZP3-P to avoid a fail of the mice mating experiment like 
with VacZP2 once again. During the mating experiment with VacZP2 the FvB/NcrL mice 
showed high aggression and corrupted the results. We decided against a de novo mice 
experiment with VacZP2, which impeded a direct comparison between VacZP2 and 
VacZP3-P in regard to contraception. The subsequent VacZP2 test in hamster enabled a 
direct comparison to the literature of Hasegawa et al. 1992, which is the only in vivo 
mating study using small animals for porcine ZP2 testing. This made an evaluation of the 
plant-made VacZP2 vaccine in comparison to common ZP vaccines possible. In further 
work the mating experiment with VacZP2 in BALB/c mice should be conducted, to obtain 
a better comparability between VacZP2 and VacZP3-P.  
In comparison to studies with the recombinant murine ZP2 and ZP3, where a sterilization 
rate in mice of over 50 % was obtained (Clydesdale et al. 2004; Hardy et al. 2003; Sun 
1999; Millar et al. 1989), our vaccines had a low spaying effect. Since ZP2 (Hasegawa et 
al. 2000) and ZP3 (Gupta et al. 2013; Paterson et al. 1992) are both critical targets to cause 
a block of sperm contact, it is also possible, that a combination of both plant-made 
vaccines results in an increased contraceptive effect.  
Due to the porcine sequence in VacZP2 and VacZP3-P, it could show a stronger effect in 
ungulates, than in rodents, like the cross-reactive PZP vaccine (Kirkpatrick et al. 2011; 
Sacco et al. 1981). Further experiments have to be conducted to test the efficacy in wild 
animals, like boar or deer, and the mucosal delivery of the antigen via CTB. The 
accumulation of ZP vaccines in fusion with the mucosal adjuvant CTB-based in edible 
tobacco seeds is a huge step forward, because it opens an opportunity of novel vaccine 
delivery (Gupta et al. 2011) 
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5.5 CTB – A critical point in the method 
The detection of free CTB molecules in the Western blot renders the quantification of 
VacZP2 and VacZP3 via CTB Elisa problematic. Since VacZP2 and VacZP3-P content is 
measured via CTB, the occurrence of free CTB leads to an overestimation of the active 
compound. This problem was solved by studies with the same problem by a transient 
precipitation of the active compound (Matoba et al. 2009) or densitometric approach via 
anti-CTB Western blot analysis (Lakshmi et al. 2013). Because precipitation of VacZP2 and 
VacZP3-P was not reversible (data not shown), free CTB molecule quantification in the 
protein extracts was conducted with the help of densitometric Western blot analysis 
against commercially available CTB as standard. The determined mass was set in relation 
to the whole amount of CTB measured via anti-CTB ELISA. The amount of free CTB is 
similar in both approaches, which exhibit a connection between the expression levels of 
the fusion proteins. 
Free CTB molecules were also present during immunization of VacZP2 and VacZP3-P, 
respectively. Free, non-antigen linked CTB is weakly immunogenic in contrast to fused CTB 
(Eriksson et al. 2003). The free CTB molecules in our vaccine should not decrease the 
immune response and may act as adjuvant improving the immune response via mucosal 
(Prabakaran et al. 2008; Asahi-Ozaki et al. 2006; Isaka et al. 2001) and parenteral route 
(Hirabayashi et al. 1990). 
5.6 Aims archieved 
The six aims (1 – 6) of the concept study were successfully achieved. (1) Two ZP vaccines, 
VacZP2 and VacZP3-P, in fusion with adjuvants were designed to block the sperm-egg 
contact. (2) Both were expressed in different stable and transient plant expression 
systems to cover special features of low costs, high scalability, long storability and high 
production time flexibility, respectively. (3) In all tested systems the vaccines were 
detected. The transient system, with the highest yield in a short period of time, was set 
as production platform. ZP vaccines were (4) purified and (5) characterized to (6) evaluate 
the immunogenicity and contraceptive efficacy in animals. The results of this study can be 
used to continue the development of a plant-made ZP vaccine, to achieve theoretically 
unlimited amounts of recombinant protein connected with low cost. In further studies an 
increase of the contraceptive effect and the way of delivery should be addressed to be 
practicle for wild life management (Gupta et al. 2011). The base is set. VacZP2 and 
VacZP3-P are fused to CTB and expressable in edible plant parts, which allows oral 
vaccination (Nochi et al. 2007; Haq et al. 1995). 
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Figure 38: Milestones in this concept were design of ZP vaccine, expression in different plant expression systems, and detection of the ZP vaccine. After evaluating 
the system with the highest yield, building up a production platform by establishing custom purification protocol with lessons learned from 
characterization. Continuous production of ZP vaccines to gain enough material to test the immunocontraceptive effect in rodent model. 
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6. Summary 
The propagation of selected populations of elephants, white-tailed deer and feral horses 
is regulated by vaccination with porcine oocyte surface proteins. An extension of this 
method to other wild mammals is limited because of high costs, composed of the 
production from pig oocytes and the mandatory parenteral injection. Recombinant 
expressions of Zona Pellucide (ZP) vaccines open the possibility for cheap upscaling. The 
main aim of the present study was to evaluate the possibility of plant-based production 
of a ZP vaccine. The methodological approach included different plants gene expression 
systems to pick the optimal production platform.  
In this work the N-terminal part of porcine ZP2 and the full-length porcine ZP3 was used 
as antigens. Both play a crucial role in fertilization and blocking, which further leads to a 
contraceptive effect in various mammalian species. The antigens are N- and C-terminally 
fused to the bacterial adjuvants cholera toxin subunit b (CTB) and tetanus toxoid830-844, 
which could make an additional adjuvant obsolete. The vaccine concentrations in the 
plant cells were measured by a CTB ELISA. 
The expression of VacZP2 and VacZP3-P was evaluated both in constitutive and transient 
expression systems, because these vaccines featured opposite advantages and 
disadvantages in production cost and duration. Under the control of the constitutive 
arcelin5-I promoter we detected 0.24 and 0.03 µgCTB mgDW-1 for VacZP2 and VacZP3-P in 
tobacco seeds, respectively. Due to the low enrichment (< 0.6 ngCTB mgDW-1) of VacZP3-P 
in pea seeds, VacZP2 in carrot cells and tobacco leaves via the constitutive CaMV35S 
promoter, these production platforms were not practical. The highest yield of both ZP 
vaccines was achieved by the viral MagnICON system in N. benthamiana, which was 
chosen to produce sufficient amounts for animal testing. The CTB concentration was 
5- times higher for VacZP2 and 4-folds higher for VacZP3-P than in the tobacco 
seed-specific expression. Both vaccines were N-glycosylated. 
Plant-derived VacZP2 and VacZP3-P showed no decrease in concentration in freeze-dried 
leaves for at least 35 and 21 weeks, respectively. Since both vaccines exhibit protein 
degradation after isolation at room temperature, purification under cooled or protease-
inhibited conditions was necessary. VacZP2 elicited a high antibody titer in FvB mice even 
without additional adjuvant. Hamsters showed also a negative effect on fertility. Two out 
of four females had no offspring in contrast to the control group were all animals bear. 
VacZP3-P stimulates the immune system of BALB/c mice even with small doses. A 
subsequent mating experiment showed a dose-dependent spaying effect with an 
offspring reduction of up to 43 % with the highest dosage.  
In summary, porcine ZP2 and ZP3 was accumulated in various plant species and organs 
via different expression systems. The recombinant expression of these proteins enables a 
cheap production and easy scale-up in comparison to pig ovaries as the common 
production platform for porcine antigens. 
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V. Supplement 
Table 5: PCR program 1 
Step   
Denaturation 95 °C 30 sec 
Primer Annealing 70 °C 30 sec 
Elongation 72 °C 90 sec 
Cycles 30  
 
Table 6: PCR program 2 „Dream60“ 
Step   
Denaturation 95 °C 30 sec 
Primer Annealing 60 °C 30 sec 
Elongation 72 °C 90 sec 
Cycles 25  
 
Table 7: PCR program 3 „Colony-PCR“ 
Step   
Denaturation 95 °C 30 sec 
Primer Annealing 55 °C 30 sec 
Elongation 72 °C 30 - 90 sec 
Cycles 26  
 
Table 8: PCR program 4 
Step   
Denaturierung 95 °C 30 sec 
Primer Annealing 60 °C 30 sec 
Elongation 72 °C 90 sec 
Zyklen 26  
 
Tabelle 5: PCR Programm 5 
Step   
Denaturierung 95 °C 30 sec 
Primer Annealing 55 °C 30 sec 
Elongation 72 °C 120 sec 
Zyklen 30  
  
96____Supplement  
 
Table 9: List of used primer 
Name Sequence 
Seq_plCH29912_fw ACAAACCCGAATCAGTACCAG 
Seq_pICH29912_rv GTGGAGAGAAAAACACTATGC 
pZP3_fw CAGCCTGTGTGGCAAGACGA 
pZP3_rev TGACAATGAAGGAGTGCCGC 
Seq_DTB_ER_3'_fw GTCGAGCTATTGACGGAGAT 
Seq_CTB_5'_rev GGCCAGCGACTCAGTATAAC 
Act-fw GCAACTGGGATGATATGGAGAA 
Act-rv GTGCCTTTGCAATCCACATCTG 
Seq_Modul SapI_r TTAAGTTCGCTAAGTTCTGG 
DTB_proof_fw GCACCCAGAACTTAGCGAAC 
DTB_proof_rev TCCAACGTAAACTGGGCTTT 
CTB_prove_fw TGCTTAGTTCCGCCTATGCT 
CTB_prove_rev GGGGTCTTGTTGTTCCACAC 
DTB_re-prove_fw CGGGCCTATCAAAAACAAGA 
DTB_re-prove_rev TCTGGTATCCGAGAACTCCAA 
pZP3_Tabak_fw ATGGTTGAATGCCAAGAAGC 
pZP3_Tabak_rev ACACGATCAGCAGGGGTAAC 
Seq_CTB_Tabak_rev TCCCTCTTGCCAGCTAAAGA 
Seq_3'_synZP3_fw TGTTGCCATAAGGGACAATG 
BsaI_repair_fw CCCGGGGGTCTCACATGGCTAGTTC 
BsaI_repair_rev GTCGACGGTCTCAAAGCTTACAGTTCGTCTTTCTC 
pJET1.2_fw CGACTCACTATAGGGAGAGCGGC 
pJET1.2_rev AAGAACATCGATTTTCCATGGCAG 
ÜEx_synZP3_NdeI CATATGACTCCCCAGAATATCACTG 
ÜEx_synZP3_XhoI CTCGAGTTACAGTTCGTCTTTCTCT 
Seq_synpZP3_r GATAGATAAGTTTCCTGCTGGTCGC 
pET28-fw TCCCGCGAAATTAATACGAC 
pET28-rv CTTTCGGGCTTTGTTAGCAG 
TMV-fw GATCCGGACGTCGAAGGTTTCGAAGG 
TMV-rev CTTGACTCTAGCTAGAGCGGCCGCTGG 
daf9 CCGACGCGGC 
CTB_new_fw CACAAATTCACACTCTTAACGACA 
CTB_new_rev TAGCCATACTTATAGCCGCAATG 
pZP2_pICH31120f GGTCTCAAGGTATAGGGGTCA 
pZP2_pICH31120r GGTCTCAAAGCTCACAGTTCGTCTTTCTCTGAGTGGTGGTGGTGGTGGTG 
CTB_new_fw CACAAATTCACACTCTTAACGACA 
CTB_new_rev TAGCCATACTTATAGCCGCAATG 
pZP2_TT_fw ATAGGGGTCAATCAGTTGGT 
pZP2_TT_rev CGCCATTCCAGGAAAGAAGT 
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Suppl. 1: Alignment of vacZP2-P with consensus sequences for plantal transcription stop. For a 
transcriptional stop consensus sequences must be in following order: UE (-60 bp), 
PE (-20 to -30 bp), T-rich (directly before CS), CS, T-rich (n…not found within 
sequence; f…found within sequence) 
 
                     10         20         30         40         50         60                 
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP2      ATGGCTAGTT CCATAAAATT GAAATTTGGC GTGTTCTTTA CAGTGCTTTT ATCATCAGCA   
ER-Signal   ~~~~~~~~~~ ~~ATAAAATT GAAATTTGGC GTGTTCTTTA CAGTGCTTTT ATCATCAGCA   
CTB         ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
GPGP        ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_1_n      TTGTAT---- ---------- ---------- ---------- ---------- ----------   
UE_2_n      TTGTAA---- ---------- ---------- ---------- ---------- ----------   
UE_3_n      TTTGTA---- ---------- ---------- ---------- ---------- ----------   
UE_4_n      TGTTGTG--- ---------- ---------- ---------- ---------- ----------   
UE_5_n      TGTGTTTTTT ---------- ---------- ---------- ---------- ----------   
PE_1_n      AATAAA---- ---------- ---------- ---------- ---------- ----------   
PE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_1_f  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_2_n  TTTTTT                                                              
CS_1        TA-------- ---------- ---------- ---------- ---------- ----------   
CS_2        CA-------- ---------- ---------- ---------- ---------- ----------   
 
                     70         80         90        100        110        120              
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP2      TATGCGCATG GTACTCCCCA GAATATCACT GATCTTTGTG CTGAGTATCA TAACACACAA   
ER-Signal   TATGCGCATG GT-------- ---------- ---------- ---------- ----------   
CTB         ~~~~~~~~~~ ~~ACTCCCCA GAATATCACT GATCTTTGTG CTGAGTATCA TAACACACAA   
GPGP        ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_1_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_2_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_3_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_4_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_5_n      ---------- ---------- ---------- ---------- ---------- ----------   
PE_1_n      ---------- ---------- ---------- ---------- ---------- ----------   
PE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_1_f  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_2_n                                                                      
CS_1        ---------- ---------- ---------- ---------- ---------- ----------   
CS_2        ---------- ---------- ---------- ---------- ---------- ----------   
 
                    130        140        150        160        170        180           
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP2      ATTCACACTC TTAACGACAA AATCTTCAGC TATACCGAAT CTTTAGCTGG CAAGAGGGAG   
ER-Signal   ---------- ---------- ---------- ---------- ---------- ----------   
CTB         ATTCACACTC TTAACGACAA AATCTTCAGC TATACCGAAT CTTTAGCTGG CAAGAGGGAG   
GPGP        ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_1_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_2_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_3_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_4_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_5_n      ---------- ---------- ---------- ---------- ---------- ----------   
PE_1_n      ---------- ---------- ---------- ---------- ---------- ----------   
PE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_1_f  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_2_n                                                                      
CS_1        ---------- ---------- ---------- ---------- ---------- ----------   
CS_2        ---------- ---------- ---------- ---------- ---------- ----------   
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                    190        200        210        220        230        240           
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP2      ATGGCAATTA TAACATTCAA GAATGGAGCA ACTTTTCAGG TTGAAGTTCC AGGATCTCAA   
ER-Signal   ---------- ---------- ---------- ---------- ---------- ----------   
CTB         ATGGCAATTA TAACATTCAA GAATGGAGCA ACTTTTCAGG TTGAAGTTCC AGGATCTCAA   
GPGP        ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_1_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_2_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_3_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_4_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_5_n      ---------- ---------- ---------- ---------- ---------- ----------   
PE_1_n      ---------- ---------- ---------- ---------- ---------- ----------   
PE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_1_f  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_2_n                                                                      
CS_1        ---------- ---------- ---------- ---------- ---------- ----------   
CS_2        ---------- ---------- ---------- ---------- ---------- ----------   
 
                    250        260        270        280        290        300           
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP2      CACATCGATT CCCAGAAGAA GGCAATTGAG AGAATGAAGG ATACATTGAG GATTGCATAT   
ER-Signal   ---------- ---------- ---------- ---------- ---------- ----------   
CTB         CACATCGATT CCCAGAAGAA GGCAATTGAG AGAATGAAGG ATACATTGAG GATTGCATAT   
GPGP        ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_1_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_2_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_3_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_4_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_5_n      ---------- ---------- ---------- ---------- ---------- ----------   
PE_1_n      ---------- ---------- ---------- ---------- ---------- ----------   
PE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~AATGAA-- ---------- ----------   
T-rich_1_f  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_2_n                                                                      
CS_1        ---------- ---------- ---------- ---------- ---------- ----------   
CS_2        ---------- ---------- ---------- ---------- ---------- ----------   
 
                    310        320        330        340        350        360           
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP2      CTCACTGAGG CAAAAGTGGA GAAACTGTGC GTATGGAATA ACAAAACACC CCATGCCATT   
ER-Signal   ---------- ---------- ---------- ---------- ---------- ----------   
CTB         CTCACTGAGG CAAAAGTGGA GAAACTGTGC GTATGGAATA ACAAAACACC CCATGCCATT   
GPGP        ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_1_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_2_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_3_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_4_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_5_n      ---------- ---------- ---------- ---------- ---------- ----------   
PE_1_n      ---------- ---------- ---------- ---------- ---------- ----------   
PE_2_f      ---------- ---------- ---------- ---------- ---------- ----------   
T-rich_1_f  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_2_n                                                                      
CS_1        ---------- ---------- ---------- ---------- ---------- ----------   
CS_2        ---------- ---------- ---------- ---------- ---------- ----------   
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                    370        380        390        400        410        420           
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP2      GCGGCTATAA GTATGGCTAA TGGTCCAGGA CCACTTAAGA TAGGGGTCAA TCAGTTGGTT   
ER-Signal   ---------- ---------- ---------- ---------- ---------- ----------   
CTB         GCGGCTATAA GTATGGCTAA T--------- ---------- ---------- ----------   
GPGP        ~~~~~~~~~~ ~~~~~~~~~~ ~GGTCCAGGA CCA------- ---------- ----------   
UE_1_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_2_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_3_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_4_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_5_n      ---------- ---------- ---------- ---------- ---------- ----------   
PE_1_n      ---------- ---------- ---------- ---------- ---------- ----------   
PE_2_f      ---------- ---------- ---------- ---------- ---------- ----------   
T-rich_1_f  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_2_n                                                                      
CS_1        ---------- ---------- ---------- ---------- ---------- ----------   
CS_2        ---------- ---------- ---------- ---------- ---------- ----------   
 
                    430        440        450        460        470        480           
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP2      AACACAGCAT TTCCTGGCAT TGTGACTTGT CATGAGAATC GTATGGTTGT GGAGTTTCCG   
ER-Signal   ---------- ---------- ---------- ---------- ---------- ----------   
CTB         ---------- ---------- ---------- ---------- ---------- ----------   
GPGP        ---------- ---------- ---------- ---------- ---------- ----------   
UE_1_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_2_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_3_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_4_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_5_n      ---------- ---------- ---------- ---------- ---------- ----------   
PE_1_n      ---------- ---------- ---------- ---------- ---------- ----------   
PE_2_f      ---------- ---------- ---------- ---------- ---------- ----------   
T-rich_1_f  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_2_n                                                                      
CS_1        ---------- ---------- ---------- ---------- ---------- ----------   
CS_2        ---------- ---------- ---------- ---------- ---------- ----------   
 
                    490        500        510        520        530        540           
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP2      AGAATTCTTG GCACTAAGAT CCAGTATACA TCTGTTGTAG ATCCTTTAGG TTTGGAGATG   
ER-Signal   ---------- ---------- ---------- ---------- ---------- ----------   
CTB         ---------- ---------- ---------- ---------- ---------- ----------   
GPGP        ---------- ---------- ---------- ---------- ---------- ----------   
UE_1_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_2_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_3_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_4_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_5_n      ---------- ---------- ---------- ---------- ---------- ----------   
PE_1_n      ---------- ---------- ---------- ---------- ---------- ----------   
PE_2_f      ---------- ---------- ---------- ---------- ---------- ----------   
T-rich_1_f  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_2_n                                                                      
CS_1        ---------- ---------- ---------- ---------- ---------- ----------   
CS_2        ---------- ---------- ---------- ---------- ---------- ----------   
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                    550        560        570        580        590        600           
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP2      ATGAACTGTA CTTACGTCCT TGATCCCGAA AATCTGACTC TCAAAGCTCC ATATGAAGCA   
ER-Signal   ---------- ---------- ---------- ---------- ---------- ----------   
CTB         ---------- ---------- ---------- ---------- ---------- ----------   
GPGP        ---------- ---------- ---------- ---------- ---------- ----------   
UE_1_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_2_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_3_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_4_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_5_n      ---------- ---------- ---------- ---------- ---------- ----------   
PE_1_n      ---------- ---------- ---------- ---------- ---------- ----------   
PE_2_f      ---------- ---------- ---------- ---------- ---------- ----------   
T-rich_1_f  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_2_n                                                                      
CS_1        ---------- ---------- ---------- ---------- ---------- ----------   
CS_2        ---------- ---------- ---------- ---------- ---------- ----------   
 
                    610        620        630        640        650        660           
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP2      TGCACAAAGA GAGTTAGAGG ACATCACCAA ATGACGATTA GGCTAATCGA CGATAATGCA   
ER-Signal   ---------- ---------- ---------- ---------- ---------- ----------   
CTB         ---------- ---------- ---------- ---------- ---------- ----------   
GPGP        ---------- ---------- ---------- ---------- ---------- ----------   
UE_1_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_2_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_3_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_4_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_5_n      ---------- ---------- ---------- ---------- ---------- ----------   
PE_1_n      ---------- ---------- ---------- ---------- ---------- ----------   
PE_2_f      ---------- ---------- ---------- ---------- ---------- ----------   
T-rich_1_f  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_2_n                                                                      
CS_1        ---------- ---------- ---------- ---------- ---------- ----------   
CS_2        ---------- ---------- ---------- ---------- ---------- ----------   
 
                    670        680        690        700        710        720           
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP2      GCTTTACGAC AAGAAGCCCT TATGTACCAC ATAAGTTGTC CAGTAATGGG TGCTGAAGGT   
ER-Signal   ---------- ---------- ---------- ---------- ---------- ----------   
CTB         ---------- ---------- ---------- ---------- ---------- ----------   
GPGP        ---------- ---------- ---------- ---------- ---------- ----------   
UE_1_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_2_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_3_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_4_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_5_n      ---------- ---------- ---------- ---------- ---------- ----------   
PE_1_n      ---------- ---------- ---------- ---------- ---------- ----------   
PE_2_f      ---------- ---------- ---------- ---------- ---------- ----------   
T-rich_1_f  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_2_n                                                                      
CS_1        ---------- ---------- ---------- ---------- ---------- ----------   
CS_2        ---------- ---------- ---------- ---------- ---------- ----------   
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                    730        740        750        760        770        780           
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP2      CCAGATCAAC ATTCAGGATC TACCATTTGC ATGAAAGACT TCATGTCCTT TACCTTCAAC   
ER-Signal   ---------- ---------- ---------- ---------- ---------- ----------   
CTB         ---------- ---------- ---------- ---------- ---------- ----------   
GPGP        ---------- ---------- ---------- ---------- ---------- ----------   
UE_1_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_2_n      -                                                                   
UE_3_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_4_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_5_n      ---------- ---------- ---------- ---------- ---------- ----------   
PE_1_n      ---------- ---------- ---------- ---------- ---------- ----------   
PE_2_f      ---------- ---------- ---------- ---------- ---------- ----------   
T-rich_1_f  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_2_n                                                                      
CS_1        ---------- ---------- ---------- ---------- ---------- ----------   
CS_2        ---------- ---------- ---------- ---------- ---------- ----------   
 
                    790        800        810        820        830        840           
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP2      TTCTTTCCTG GAATGGCGTG TACAATTGAA GGAAGAAAGA AGCAGTACAT TAAAGCCAAT   
ER-Signal   ---------- ---------- ---------- ---------- ---------- ----------   
CTB         ---------- ---------- ---------- ---------- ---------- ----------   
GPGP        ---------- ---------- ---------- ---------- ---------- ----------   
UE_1_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_2_n                                                                          
UE_3_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_4_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_5_n      ---------- ---------- ---------- ---------- ---------- ----------   
PE_1_n      ---------- ---------- ---------- ---------- ---------- ----------   
PE_2_f      ---------- ---------- ---------- ---------- ---------- ----------   
T-rich_1_f  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ TTTTCT---- ----------   
T-rich_2_n                                                                      
CS_1        ---------- ---------- ---------- ---------- ---------- ----------   
CS_2        ---------- ---------- ---------- ---------- ---------- ----------   
 
                    850        860        870        880        890        900           
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP2      AGCAAGTTTA TAGGGATAAC CGAACTAGAG AACCTGTACT TTCAAGGTGG ATCCCATCAT   
ER-Signal   ---------- ---------- ---------- ---------- ---------- ----------   
CTB         ---------- ---------- ---------- ---------- ---------- ----------   
GPGP        ---------- ---------- ---------- ---------- ---------- ----------   
UE_1_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_2_n                                                                          
UE_3_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_4_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_5_n      ---------- ---------- ---------- ---------- ---------- ----------   
PE_1_n      ---------- ---------- ---------- ---------- ---------- ----------   
PE_2_f      ---------- ---------- ---------- ---------- ---------- ----------   
T-rich_1_f  ---------- ---------- ---------- ---------- ---------- ----------   
T-rich_2_n                                                                      
CS_1        ---------- ---------- ---------- ---------- ---------- ----------   
CS_2        ---------- ---------- ---------- ---------- ---------- ----------   
 
                    910        920        930        940        950        960           
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP2      CACCATCACC ACTCAGAGAA AGACGAACTG TAA------- ---------- ----------   
ER-Signal   ---------- ---------- ---------- ---------- ---------- ----------   
CTB         ---------- ---------- ---------- ---------- ---------- ----------   
GPGP        ---------- ---------- ---------- ---------- ---------- ----------   
UE_1_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_2_n                                                                          
UE_3_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_4_n      ---------- ---------- ---------- ---------- ---------- ----------   
UE_5_n      ---------- ---------- ---------- ---------- ---------- ----------   
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Suppl. 2: Western blot analysis of VacZP3-P. (A) Anti-CTB and (B) anti-histidine Western blot 
analysis of VacZP3-P in crude N. benthamiana protein extract, separated in a 12 % 
SDS-PAGE. (C) Anti-CTB Western blot analysis of VacZP3-P in crude tobacco protein 
extract, separated in a 6 % SDS-PAGE. 
 
 
Suppl. 3: GM1 and anti-CTB binding assay of VacZP3-P (n = 2) 
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Suppl. 4: N. benthamiana protein extract of transiently expressed VacZP3-P detected in anti-CTB 
Western blot analysis. Buffer I: Protein extraction buffer without protease 
inhibitor mix (see material & methods); Buffer II: Davoodi-Semiromi et al. 2010 
 
 
Suppl. 5: Densitometric analysis of free CTB molecules in purified VacZP3-P (in 1 x PBS pH 7.2). 
(A) Digitally colour-inverted and desaturated Anti-CTB Western blot analysis. Lane 
1...10 ng CTB Standard; 2...25 ng CTB; 3...50 ng CTB; 4...300 ng CTB, 5...1330 ng 
VacZP3-P (determined in anti-CTB ELISA). (B) Standard curve of white pixel 
densities from CTB standard (yellow). 
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Suppl. 6: Alignment of vacZP3-P with consensus sequences for plantal transcription stop. For a 
transcriptional stop consensus sequences must be in following order: UE (-60 bp), 
PE (-20 to -30 bp), T-rich (directly before CS), CS, T-rich (n…not found within 
sequence; f…found within sequence) 
 
                     10         20         30         40         50         60                 
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP3      ATGGCTAGTT CCATAAAATT GAAATTTGGC GTGTTCTTTA CAGTGCTTTT ATCATCAGCA   
ER-Signal   ~~~~~~~~~~ ~~ATAAAATT GAAATTTGGC GTGTTCTTTA CAGTGCTTTT ATCATCAGCA   
CTB         ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
GPGP        ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_1_n      TTGTAT                                                              
UE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_3_n      TTTGTA                                                              
UE_4_n      TGTTGTG                                                             
UE_5_n      TGTGTTTTTT                                                          
PE_1_n      AATAAA                                                              
PE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_1_f  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_2_n  TTTTTT                                                              
CS_1        TA                                                                  
CS_2        CA                                                                  
 
                     70         80         90        100        110        120              
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP3      TATGCGCATG GTACTCCCCA GAATATCACT GATCTTTGTG CTGAGTATCA TAACACACAA   
ER-Signal   TATGCGCATG GT                                                       
CTB         ~~~~~~~~~~ ~~ACTCCCCA GAATATCACT GATCTTTGTG CTGAGTATCA TAACACACAA   
GPGP        ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_1_n                                                                          
UE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_3_n                                                                          
UE_4_n                                                                          
UE_5_n                                                                          
PE_1_n                                                                          
PE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_1_f  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_2_n                                                                      
CS_1                                                                            
CS_2                                                                            
 
                    130        140        150        160        170        180           
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP3      ATTCACACTC TTAACGACAA AATCTTCAGC TATACCGAAT CTTTAGCTGG CAAGAGGGAG   
ER-Signal                                                                       
CTB         ATTCACACTC TTAACGACAA AATCTTCAGC TATACCGAAT CTTTAGCTGG CAAGAGGGAG   
GPGP        ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_1_n                                                                          
UE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_3_n                                                                          
UE_4_n                                                                          
UE_5_n                                                                          
PE_1_n                                                                          
PE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_1_f  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_2_n                                                                      
CS_1                                                                            
CS_2                                                                            
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                    190        200        210        220        230        240           
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP3      ATGGCAATTA TAACATTCAA GAATGGAGCA ACTTTTCAGG TTGAAGTTCC AGGATCTCAA   
ER-Signal                                                                       
CTB         ATGGCAATTA TAACATTCAA GAATGGAGCA ACTTTTCAGG TTGAAGTTCC AGGATCTCAA   
GPGP        ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_1_n                                                                          
UE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_3_n                                                                          
UE_4_n                                                                          
UE_5_n                                                                          
PE_1_n                                                                          
PE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_1_f  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_2_n                                                                      
CS_1                                                                            
CS_2                                                                            
 
                    250        260        270        280        290        300           
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP3      CACATCGATT CCCAGAAGAA GGCAATTGAG AGAATGAAGG ATACATTGAG GATTGCATAT   
ER-Signal                                                                       
CTB         CACATCGATT CCCAGAAGAA GGCAATTGAG AGAATGAAGG ATACATTGAG GATTGCATAT   
GPGP        ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_1_n                                                                          
UE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_3_n                                                                          
UE_4_n                                                                          
UE_5_n                                                                          
PE_1_n                                                                          
PE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~AATGAA                           
T-rich_1_f  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_2_n                                                                      
CS_1                                                                            
CS_2                                                                            
 
                    310        320        330        340        350        360           
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP3      CTCACTGAGG CAAAAGTGGA GAAACTGTGC GTATGGAATA ACAAAACACC CCATGCCATT   
ER-Signal                                                                       
CTB         CTCACTGAGG CAAAAGTGGA GAAACTGTGC GTATGGAATA ACAAAACACC CCATGCCATT   
GPGP        ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_1_n                                                                          
UE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_3_n                                                                          
UE_4_n                                                                          
UE_5_n                                                                          
PE_1_n                                                                          
PE_2_f                                                                          
T-rich_1_f  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_2_n                                                                      
CS_1                                                                            
CS_2                                                                            
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                    370        380        390        400        410        420           
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP3      GCGGCTATAA GTATGGCTAA TGGTCCAGGA CCACTTAAGC AGCCTGTCTG GCAAGACGAA   
ER-Signal                                                                       
CTB         GCGGCTATAA GTATGGCTAA T                                             
GPGP        ~~~~~~~~~~ ~~~~~~~~~~ ~GGTCCAGGA CCA                                
UE_1_n                                                                          
UE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_3_n                                                                          
UE_4_n                                                                          
UE_5_n                                                                          
PE_1_n                                                                          
PE_2_f                                                                          
T-rich_1_f  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_2_n                                                                      
CS_1                                                                            
CS_2                                                                            
 
                    430        440        450        460        470        480           
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP3      GGTCAGAGAT TACGACCTAG TAAGCCTCCG ACAGTTATGG TTGAATGCCA AGAAGCCCAA   
ER-Signal                                                                       
CTB                                                                             
GPGP                                                                            
UE_1_n                                                                          
UE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_3_n                                                                          
UE_4_n                                                                          
UE_5_n                                                                          
PE_1_n                                                                          
PE_2_f                                                                          
T-rich_1_f  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_2_n                                                                      
CS_1                                                                            
CS_2                                                                            
 
                    490        500        510        520        530        540           
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP3      TTGGTCGTGA TTGTCTCTAA GGACTTATTT GGCACTGGTA AACTGATTCG TCCAGCAGAT   
ER-Signal                                                                       
CTB                                                                             
GPGP                                                                            
UE_1_n                                                                          
UE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_3_n                                                                          
UE_4_n                                                                          
UE_5_n                                                                          
PE_1_n                                                                          
PE_2_f                                                                          
T-rich_1_f  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_2_n                                                                      
CS_1                                                                            
CS_2                                                                            
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                    550        560        570        580        590        600           
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP3      TTGAGCCTTG GACCAGCCAA ATGTGAACCC CTAGTCTCAC AAGATACCGA TGCAGTGGTT   
ER-Signal                                                                       
CTB                                                                             
GPGP                                                                            
UE_1_n                                                                          
UE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_3_n                                                                          
UE_4_n                                                                          
UE_5_n                                                                          
PE_1_n                                                                          
PE_2_f                                                                          
T-rich_1_f  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_2_n                                                                      
CS_1                                                                            
CS_2                                                                            
 
                    610        620        630        640        650        660           
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP3      AGGTTCGAAG TAGGGCTTCA TGAATGTGGT TCTTCATTGC AAGTTACGGA TGATGCCCTT   
ER-Signal                                                                       
CTB                                                                             
GPGP                                                                            
UE_1_n                                                                          
UE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_3_n                                                                          
UE_4_n                                                                          
UE_5_n                                                                          
PE_1_n                                                                          
PE_2_f                                                                          
T-rich_1_f  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_2_n                                                                      
CS_1                                                                            
CS_2                                                                            
 
                    670        680        690        700        710        720           
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP3      GTTTACTCTA CCTTCTTGAG ACACGATCCG CGACCAGCAG GAAACTTATC TATCTTGAGG   
ER-Signal                                                                       
CTB                                                                             
GPGP                                                                            
UE_1_n                                                                          
UE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_3_n                                                                          
UE_4_n                                                                          
UE_5_n                                                                          
PE_1_n                                                                          
PE_2_f                                                                          
T-rich_1_f  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_2_n                                                                      
CS_1                                                                            
CS_2                                                                            
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                    730        740        750        760        770        780           
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP3      ACAAATAGGG CAGAAGTGCC TATCGAGTGC CATTATCCTA GACAAGGCAA TGTTAGTAGT   
ER-Signal                                                                       
CTB                                                                             
GPGP                                                                            
UE_1_n                                                                          
UE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_3_n                                                                          
UE_4_n                                                                          
UE_5_n                                                                          
PE_1_n                                                                          
PE_2_f                                                                          
T-rich_1_f  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
T-rich_2_n                                                                      
CS_1                                                                            
CS_2                                                                            
 
                    790        800        810        820        830        840           
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP3      TGGGCCATTC TGCCAACATG GGTACCGTTT CGTACGACCG TTTTCTCTGA GGAGAAACTC   
ER-Signal                                                                       
CTB                                                                             
GPGP                                                                            
UE_1_n                                                                          
UE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_3_n                                                                          
UE_4_n                                                                          
UE_5_n                                                                          
PE_1_n                                                                          
PE_2_f                                                                          
T-rich_1_f  ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ TTTTCT                  
T-rich_2_n                                                                      
CS_1                                                                            
CS_2                                                                            
 
                    850        860        870        880        890        900           
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP3      GTCTTTTCAT TGAGATTGAT GGAGGAAAAT TGGTCAGCTG AGAAGATGAC TCCAACATTT   
ER-Signal                                                                       
CTB                                                                             
GPGP                                                                            
UE_1_n                                                                          
UE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_3_n                                                                          
UE_4_n                                                                          
UE_5_n                                                                          
PE_1_n                                                                          
PE_2_f                                                                          
T-rich_1_f                                                                      
T-rich_2_n                                                                      
CS_1                                                                            
CS_2                                                                            
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                    910        920        930        940        950        960           
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP3      CAGCTTGGGG ACAGAGCTCA TCTTCAGGCT CAAGTCCATA CTGGTTCACA CGTTCCTCTA   
ER-Signal                                                                       
CTB                                                                             
GPGP                                                                            
UE_1_n                                                                          
UE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_3_n                                                                          
UE_4_n                                                                          
UE_5_n                                                                          
PE_1_n                                                                          
PE_2_f                                                                          
T-rich_1_f                                                                      
T-rich_2_n                                                                      
CS_1                                                                            
CS_2                                                                            
 
                    970        980        990        1000       1010       1020          
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP3      AGACTCTTTG TTGACCATTG CGTTGCTACA CTCACTCCAG ATTGGAACAC TAGTCCTTCT   
ER-Signal                                                                       
CTB                                                                             
GPGP                                                                            
UE_1_n                                                                          
UE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_3_n                                                                          
UE_4_n                                                                          
UE_5_n                                                                          
PE_1_n                                                                          
PE_2_f                                                                          
T-rich_1_f                                                                      
T-rich_2_n                                                                      
CS_1                                                                            
CS_2                                                                            
 
                    1030       1040       1050       1060       1070       1080          
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP3      CATACGATCG TAGACTTTCA CGGGTGTTTA GTAGATGGCC TAACTGAAGC TTCTTCTGCA   
ER-Signal                                                                       
CTB                                                                             
GPGP                                                                            
UE_1_n                                                                          
UE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_3_n                                                                          
UE_4_n                                                                          
UE_5_n                                                                          
PE_1_n                                                                          
PE_2_f                                                                          
T-rich_1_f                                                                      
T-rich_2_n                                                                      
CS_1                                                                            
CS_2                                                                            
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                    1090       1100       1110       1120       1130       1140          
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP3      TTCAAAGCGC CTAGACCTGG TCCAGAGACT CTCCAATTCA CTGTGGATGT GTTCCACTTT   
ER-Signal                                                                       
CTB                                                                             
GPGP                                                                            
UE_1_n                                                                          
UE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_3_n                                                                          
UE_4_n                                                                          
UE_5_n                                                                          
PE_1_n                                                                          
PE_2_f                                                                          
T-rich_1_f                                                                      
T-rich_2_n                                                                      
CS_1                                                                            
CS_2                                                                            
 
                    1150       1160       1170       1180       1190       1200          
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP3      GCTAATGATT CTAGAAACAC AATATACATT ACCTGTCATC TTAAAGTTAC CCCTGCTGAT   
ER-Signal                                                                       
CTB                                                                             
GPGP                                                                            
UE_1_n                                                                          
UE_2_f      ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~   
UE_3_n                                                                          
UE_4_n                                                                          
UE_5_n                                                                          
PE_1_n                                                                          
PE_2_f                                                                          
T-rich_1_f                                                                      
T-rich_2_n                                                                      
CS_1                                                                            
CS_2                                                                            
 
                    1210       1220       1230       1240       1250       1260          
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP3      CGTGTTCCCG ATCAGCTTAA TAAGGCTTGT TCTTTTAGCA AATCCAGCAA TAGGTGGAGT   
ER-Signal                                                                       
CTB                                                                             
GPGP                                                                            
UE_1_n                                                                          
UE_2_f      ~~~~~~~~~~ ~TTGTAA                                                  
UE_3_n                                                                          
UE_4_n                                                                          
UE_5_n                                                                          
PE_1_n                                                                          
PE_2_f                                                                          
T-rich_1_f                                                                      
T-rich_2_n                                                                      
CS_1                                                                            
CS_2                                                                            
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                    1270       1280       1290       1300       1310       1320          
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP3      CCAGTAGAAG GTCCAGCTGT GATTTGCAGA TGTTGCCATA AGGGACAATG TGGAACTCCT   
ER-Signal                                                                       
CTB                                                                             
GPGP                                                                            
UE_1_n                                                                          
UE_2_f                                                                          
UE_3_n                                                                          
UE_4_n                                                                          
UE_5_n                                                                          
PE_1_n                                                                          
PE_2_f                                                                          
T-rich_1_f                                                                      
T-rich_2_n                                                                      
CS_1                                                                            
CS_2                                                                            
 
                    1330       1340       1350       1360       1370       1380          
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP3      TCCTTGTCAT GTACAATTGA AGGAAGAAAG AAGCAGTACA TTAAAGCCAA TAGCAAGTTT   
ER-Signal                                                                       
CTB                                                                             
GPGP                                                                            
UE_1_n                                                                          
UE_2_f                                                                          
UE_3_n                                                                          
UE_4_n                                                                          
UE_5_n                                                                          
PE_1_n                                                                          
PE_2_f                                                                          
T-rich_1_f                                                                      
T-rich_2_n                                                                      
CS_1                                                                            
CS_2                                                                            
 
                    1390       1400       1410       1420       1430       1440          
            ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
VacZP3      ATAGGGATAA CCGAACTAGA GAACCTGTAC TTTCAAGGTG GATCCCATCA TCACCATCAC   
ER-Signal                                                                       
CTB                                                                             
GPGP                                                                            
UE_1_n                                                                          
UE_2_f                                                                          
UE_3_n                                                                          
UE_4_n                                                                          
UE_5_n                                                                          
PE_1_n                                                                          
PE_2_f                                                                          
T-rich_1_f                                                                      
T-rich_2_n                                                                      
CS_1                                                                            
CS_2                                                                             
 
                    1450       1460    
            ....|....| ....|....| .... 
VacZP3      CACTCAGAGA AAGACGAACT GTAA  
ER-Signal                               
CTB                                     
GPGP                                    
UE_1_n                                  
UE_2_f                                  
UE_3_n                                  
UE_4_n                                  
UE_5_n                                  
PE_1_n                                  
PE_2_f                                  
T-rich_1_f                              
T-rich_2_n                              
CS_1                                    
CS_2                                    
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Suppl. 7: Antibody titer of mice immunized with VacZP2 after 0 and 21 days. Primary vaccination 
was done on day 2. Sera were diluted 1:100. Error bars show standard deviation. 
Asterisk show significant difference (p < 0.05, Tukey-HSD)
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